

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptasxs1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

NEWS 35 JAN 28 MEDLINE and LMedLINE reloaded with enhancements
NEWS 36 FEB 08 STN Express, Version 8.3, now available
NEWS 37 FEB 20 PCI now available as a replacement to DPCI

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:46:00 ON 21 FEB 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:46:10 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9
DICTIONARY FILE UPDATES: 20 FEB 2008 HIGHEST RN 1004854-20-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s N-tert-butyl-2-(6-(phenylethynyl)pyridin-3-yl)imidazo[2,1-a]isoquinolin-3-amine
MISSING OPERATOR 'T-BUTYL-2-(6-'

=> s N-t-butyl-2-(6-(phenylethynyl)pyridin-3-yl)imidazo[2,1-a]isoquinolin-3-amine
MISSING OPERATOR 'T-BUTYL-2-(6-'

=> s [2-(5-phenylethynyl-thiophen-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine

MISSING OPERATOR '[2-(5-PHENYLET'

```
=> s 2-5-phenylethynyl-thiophen-2-yl-imidazol,2-apyridin-3-yl-amine
      25131542 2
      14028847 5
           23203 PHENYLETHYNYL
           37978 THIOPHEN
      25131542 2
      18593051 YL
           0 IMIDAZO1,2
           0 APYRIDIN
      20034661 3
      18593051 YL
      1855985 AMINE
L1      0 2-5-PHENYLETHYNYL-THIOPHEN-2-YL-IMIDAZO1,2-APYRIDIN-3-YL-AMINE
           (2(W)5(W)PHENYLETHYNYL(W)THIOPHEN(W)2(W)YL(W)IMIDAZO1,2(W)APYR
           IDIN(W)3(W)YL(W)AMINE)
```


```
=> benzene
BENZENE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s benzene
L2      2255706 BENZENE
```

```
=> 12
L2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> d 12
```

```
L2      ANSWER 1 OF 2255706  REGISTRY  COPYRIGHT 2008 ACS on STN
RN      1004619-84-4  REGISTRY
ED      Entered STN: 19 Feb 2008
CN      Benzenemethanamine,  $\alpha$ -(2-chloroethyl)-4-methoxy- (CA
      INDEX NAME)
MF      C10 H14 Cl N O
CI      COM
SR      CA
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	66.10	66.31

FILE 'CAPLUS' ENTERED AT 14:48:52 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2008 VOL 148 ISS 8
FILE LAST UPDATED: 20 Feb 2008 (20080220/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 10524989/pn
L3 0 10524989/PN

=>
Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptasxs1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 02	CA/CAPlus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	3	OCT 19	BEILSTEIN updated with new compounds
NEWS	4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	5	NOV 19	WPIX enhanced with XML display format
NEWS	6	NOV 30	ICSD reloaded with enhancements
NEWS	7	DEC 04	LINPADOCDB now available on STN
NEWS	8	DEC 14	BEILSTEIN pricing structure to change
NEWS	9	DEC 17	USPATOLD added to additional database clusters
NEWS	10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	11	DEC 17	DGENE now includes more than 10 million sequences
NEWS	12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	14	DEC 17	CA/CAPlus enhanced with new custom IPC display formats
NEWS	15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD

NEWS 16 JAN 02 STN pricing information for 2008 now available
 NEWS 17 JAN 16 CAS patent coverage enhanced to include exemplified
 prophetic substances
 NEWS 18 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new
 custom IPC display formats
 NEWS 19 JAN 28 MARPAT searching enhanced
 NEWS 20 JAN 28 USGENE now provides USPTO sequence data within 3 days
 of publication
 NEWS 21 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 22 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 23 FEB 08 STN Express, Version 8.3, now available
 NEWS 24 FEB 20 PCI now available as a replacement to DPCI
 NEWS 25 FEB 25 IFIREF reloaded with enhancements
 NEWS 26 FEB 25 IMSPRODUCT reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:42:54 ON 26 FEB 2008

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 13:43:05 ON 26 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 26 Feb 2008 VOL 148 ISS 9
 FILE LAST UPDATED: 25 Feb 2008 (20080225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
 They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s halpha2 receptors
      0 HALPHA2
      679883 RECEPTORS
L1      0 HALPHA2 RECEPTORS
          (HALPHA2 (W) RECEPTORS)

=> s h-alpha-2 receptors
      2849529 H
      1746473 ALPHA
      9495929 2
      679883 RECEPTORS
L2      0 H-ALPHA-2 RECEPTORS
          (H (W) ALPHA (W) 2 (W) RECEPTORS)
```

```
=> s receptors and adrenergic
      679883 RECEPTORS
      77127 ADRENERGIC
L3      39489 RECEPTORS AND ADRENERGIC
```

```
=> s l3 and alpha
      1746473 ALPHA
L4      22726 L3 AND ALPHA
```

```
=> s l4 and 2
      9495929 2
L5      14228 L4 AND 2
```

```
=> s l3 and (alpha with 2)
      1746473 ALPHA
      9495929 2
      110851 ALPHA WITH 2
          (ALPHA (1W) 2)
L6      8598 L3 AND (ALPHA WITH 2)
```

```
=> l6 and review
L6 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s l6 and review
      2296318 REVIEW
L7      473 L6 AND REVIEW
```

```
=> l7 and (depression or anxiety or movement or psychosis or weight or anxiolytic
or parkinson's)
L7 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> s l7 and (depression or anxiety or movement or psychosis or weight or anxiolytic
or parkinson's)
MISMATCHED QUOTE 'PARKINSON'S'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.
```

```
=> s l7 and (depression or anxiety or movement or psychosis or weight or anxiolytic
or parkinson)
```

86659 DEPRESSION
18752 ANXIETY
125334 MOVEMENT
6697 PSYCHOSIS
156115 WEIGHT
8029 ANXIOLYTIC
25777 PARKINSON
L8 44 L7 AND (DEPRESSION OR ANXIETY OR MOVEMENT OR PSYCHOSIS OR WEIGHT
OR ANXIOLYTIC OR PARKINSON)

=> s 18

86659 DEPRESSION
18752 ANXIETY
125334 MOVEMENT
6697 PSYCHOSIS
156115 WEIGHT
8029 ANXIOLYTIC
25777 PARKINSON
L9 44 L7 AND (DEPRESSION OR ANXIETY OR MOVEMENT OR PSYCHOSIS OR WEIGHT
OR ANXIOLYTIC OR PARKINSON)

=> d 18

L8 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1353951 CAPLUS
TI Agmatine metabolic pathway and spectrum of activity in brain
AU Halaris, Angelos; Plietz, John
CS Department of Psychiatry and Behavioral Neurosciences, Loyola University
Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA
SO CNS Drugs (2007), 21(11), 885-900
CODEN: CNDREF; ISSN: 1172-7047
PB Wolters Kluwer Health
DT Journal; General Review
LA English

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	61.33	61.54

FILE 'STNGUIDE' ENTERED AT 13:46:57 ON 26 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 22, 2008 (20080222/UP).

=> d 18 2-10

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L8 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:994117 CAPLUS
DN 147:419078
TI Duloxetine. A review of its use in the treatment of major
depressive disorder
AU Frampton, James E.; Plosker, Greg L.
CS Wolters Kluwer Health | Adis, Auckland, N. Z.
SO CNS Drugs (2007), 21(7), 581-609

CODEN: CNDREF; ISSN: 1172-7047

PB Wolters Kluwer Health
DT Journal; General Review
LA English

RE.CNT 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1039299 CAPLUS
DN 147:22182
TI New pharmacologic horizons in the treatment of Parkinson disease
AU Bonuccelli, Ubaldo; Del Dotto, Paolo
CS Department of Neurocience, University of Pisa and Neurology Unit, Pisa, Italy
SO Neurology (2006), 67(7, Suppl. 2), S30-S38
CODEN: NEURAI; ISSN: 0028-3878
PB Lippincott Williams & Wilkins
DT Journal; General Review
LA English
RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:984781 CAPLUS
DN 146:513215
TI Genetics of antipsychotic treatment emergent weight gain in schizophrenia
AU Mueller, Daniel J.; Kennedy, James L.
CS Department of Psychiatry, Charite University Medicine Berlin, Berlin, 10559, Germany
SO Pharmacogenomics (2006), 7(6), 863-887
CODEN: PARMFL; ISSN: 1462-2416
PB Future Medicine Ltd.
DT Journal; General Review
LA English
RE.CNT 180 THERE ARE 180 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:173864 CAPLUS
DN 145:158696
TI The effects of serotonin uptake inhibitors on platelet serotonin: from basic to clinical research
AU Muck-Seler, Dorotea; Pivac, Nela; Sagud, Marina; Mustapic, Maja; Jakovljevic, Miro
CS Rudjer Boskovic Institute, Zagreb, Croatia
SO Trends in Serotonin Uptake Inhibitor Research (2005), 29-53. Editor(s): Shirley, Anne C. Publisher: Nova Science Publishers, Inc., Hauppauge, N. Y.
CODEN: 69HVPE; ISBN: 1-59454-338-0
DT Conference; General Review
LA English
RE.CNT 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:107038 CAPLUS
DN 145:55182
TI Drugs in development for Parkinson's disease: an update
AU Johnston, Tom H.; Brotchie, Jonathan M.
CS Toronto Western Research Institute Toronto Western Hospital, University Health Network, Toronto, ON, M5T 2S8, Can.

SO Current Opinion in Investigational Drugs (Thomson Scientific) (2005),
Volume Date 2006, 7(1), 25-32
CODEN: COIDAZ; ISSN: 1472-4472
PB Thomson Scientific
DT Journal; General Review
LA English
RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1050229 CAPLUS
DN 143:359326
TI α 1-Adrenoceptors as potential therapeutic targets
AU Sarma, P. K. S.; Tiwari, Atul; Pal, Arani
CS Department of Medicinal Chemistry-NDDR, Ranbaxy Research Laboratories,
Gurgaon(Haryana), 122001, India
SO Expert Opinion on Therapeutic Patents (2005), 15(10), 1333-1351
CODEN: EOTPEG; ISSN: 1354-3776
PB Ashley Publications Ltd.
DT Journal; General Review
LA English
RE.CNT 136 THERE ARE 136 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1040300 CAPLUS
DN 144:184743
TI Does the panic attack activate the hypothalamic-pituitary-adrenal axis?
AU Graeff, Frederico G.; Garcia-Leal, Cybele; Del-Ben, Cristina M.;
Guimaraes, Francisco S.
CS Departamento de Neurologia, Psiquiatria e Psicologia Medica, Hospital das
Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao
Paulo, Ribeirao Preto, SP, 14048-900, Brazil
SO Anais da Academia Brasileira de Ciencias (2005), 77(3), 477-491
CODEN: AABCAD; ISSN: 0001-3765
PB Academia Brasileira de Ciencias
DT Journal; General Review
LA English
RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:662977 CAPLUS
DN 143:378838
TI Risperidone. A review of its use in the treatment of bipolar
mania
AU Fenton, Caroline; Scott, Lesley J.
CS Adis International Limited, Auckland, N. Z.
SO CNS Drugs (2005), 19(5), 429-444
CODEN: CNDREF; ISSN: 1172-7047
PB Adis International Ltd.
DT Journal; General Review
LA English
RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:479092 CAPLUS
DN 143:125559
TI Novel pharmacological strategies for motor complications in
Parkinson's disease
AU Konitsiotis, Spiros

CS Department of Neurology, University of Ioannian Medical School, Ioannina,
GR-45110, Greece
SO Expert Opinion on Investigational Drugs (2005), 14(4), 377-392
CODEN: EOIDER; ISSN: 1354-3784
PB Ashley Publications Ltd.
DT Journal; General Review
LA English
RE.CNT 155 THERE ARE 155 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:42:54 ON 26 FEB 2008)

FILE 'CAPLUS' ENTERED AT 13:43:05 ON 26 FEB 2008

L1 0 S HALPHA2 RECEPTORS
L2 0 S H-ALPHA-2 RECEPTORS
L3 39489 S RECEPTORS AND ADRENERGIC
L4 22726 S L3 AND ALPHA
L5 14228 S L4 AND 2
L6 8598 S L3 AND (ALPHA WITH 2)
L7 473 S L6 AND REVIEW
L8 44 S L7 AND (DEPRESSION OR ANXIETY OR MOVEMENT OR PSYCHOSIS OR WEI
L9 44 S L8

FILE 'STNGUIDE' ENTERED AT 13:46:57 ON 26 FEB 2008

FILE 'CAPLUS' ENTERED AT 13:47:12 ON 26 FEB 2008

FILE 'STNGUIDE' ENTERED AT 13:47:13 ON 26 FEB 2008

=>

=> d 19 11-20

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L9 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:275002 CAPLUS
DN 143:319199
TI Pathophysiology of Parkinson's disease, neurochemical pathology:
other neurotransmitters
AU Mizuno, Yoshikuni
CS Department of Neurology, Juntendo University School of Medicine, Tokyo,
Japan
SO Parkinson's Disease (2005), 443-477. Editor(s): Ebadi, Manuchair;
Pfeiffer, Ronald E. Publisher: CRC Press LLC, Boca Raton, Fla.
CODEN: 69GSAJ; ISBN: 0-8493-1590-5
DT Conference; General Review
LA English
RE.CNT 220 THERE ARE 220 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:249222 CAPLUS
DN 143:70724
TI CNS targets for multi-functional drugs in the treatment of Alzheimer's and
Parkinson's diseases
AU Youdim, M. B. H.; Buccafusco, J. J.
CS Technion-Rappaport Family-Faculty of Medicine, Eve Topf and US National

Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases,
Haifa, Israel
SO Journal of Neural Transmission (2005), 112(4), 519-537
CODEN: JNTRF3; ISSN: 0300-9564
PB Springer Wien
DT Journal; General Review
LA English
RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:320196 CAPLUS
DN 141:86353
TI Central monoamines and their role in major depression
AU Elhwuegi, Abdalla Salem
CS Faculty of Pharmacy and Health Sciences, Department of Pharmacology and
Toxicology, Ajman University of Science and Technology (AUST) Network, Abu
Dhabi, United Arab Emirates
SO Progress in Neuro-Psychopharmacology & Biological Psychiatry (2004),
28(3), 435-451
CODEN: PNPPD7; ISSN: 0278-5846
PB Elsevier Science B.V.
DT Journal; General Review
LA English
RE.CNT 147 THERE ARE 147 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:157387 CAPLUS
DN 139:239380
TI Duloxetine Eli Lilly
AU Anttila, Sami; Leinonen, Esa
CS Department of Psychogeriatrics, Tampere University Hospital, Pitkaniemi,
FIN-33380, Finland
SO Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2002), 3(8),
1217-1221
CODEN: COIDAZ; ISSN: 1472-4472
PB PharmaPress Ltd.
DT Journal; General Review
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:151546 CAPLUS
DN 139:46227
TI New approaches in the treatment of overactive bladder: Targeting
adrenergic receptors and neurokinin receptors
AU Ishizuka, O.
CS Department of Urology, Shinshu University School of Medicine, Matsumoto,
390-8621, Japan
SO Current Medicinal Chemistry: Central Nervous System Agents (2003), 3(1),
43-47
CODEN: CMCCCO; ISSN: 1568-0150
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:836902 CAPLUS

DN 138:150965
TI Psychiatric disorders
AU Gurguis, George N. M.; Rush, A. John
CS Department of Psychiatry, Dallas Veterans Administration Medical Center
and University of Texas Southwestern Medical Center, Dallas, TX, USA
SO Platelets (2002), 513-537. Editor(s): Michelson, Alan D. Publisher:
Academic Press, San Diego, Calif.
CODEN: 69DFK9; ISBN: 0-12-493951-1
DT Conference; General Review
LA English
RE.CNT 449 THERE ARE 449 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:50205 CAPLUS
DN 137:118858
TI A review of the pharmacological and clinical profile of
mirtazapine
AU Anttila, Sami A. K.; Leinonen, Esa V. J.
CS Ikaalinen Mental Health Center, Department of Psychiatry, Tampere
University Hospital, FIN-33380, Finland
SO CNS Drug Reviews (2001), 7(3), 249-264
CODEN: CDREFB; ISSN: 1080-563X
PB Neva Press
DT Journal; General Review
LA English
RE.CNT 103 THERE ARE 103 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:782179 CAPLUS
DN 136:128417
TI Antidepressant pharmacotherapy
AU Retamal C., Pedro
CS Departamento de Psiquiatria, Facultad de Medicina, Universidad de Chile,
Santiago de Chile, Chile
SO Revista Medica de Chile (2001), 129(7), 813-818
CODEN: RMCHAW; ISSN: 0034-9887
PB Sociedad Medica de Santiago
DT Journal; General Review
LA Spanish
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:554359 CAPLUS
DN 136:132382
TI Clinical and molecular genetics of ADHD and Tourette syndrome: Two related
polygenic disorders
AU Comings, David E.
CS Department of Medical Genetics, City of Hope Medical Center, Duarte, CA,
91010, USA
SO Annals of the New York Academy of Sciences (2001), 931(Adult Attention
Deficit Disorder), 50-83
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal; General Review
LA English
RE.CNT 218 THERE ARE 218 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:120294 CAPLUS
DN 134:217258
TI Review: reticuloruminal motility - a pharmacological target with
a difference?
AU Leek, B. F.
CS Department of Veterinary Physiology & Biochemistry, University College
Dublin, Dublin, Ire.
SO Veterinary Quarterly (2001), 23(1), 26-31
CODEN: VEQUDU; ISSN: 0165-2176
PB Royal Netherlands Veterinary Association
DT Journal; General Review
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 18 21-30

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L8 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:468525 CAPLUS
DN 133:175238
TI Mechanisms regulating hypoxic respiratory depression during
fetal and postnatal life
AU Bissonnette, John M.
CS Departments of Obstetrics and Gynecology and Cell and Developmental
Biology, Oregon Health Sciences University, Portland, OR, 97201-3098, USA
SO American Journal of Physiology (2000), 278(6, Pt. 2), R1391-R1400
CODEN: AJPHAP; ISSN: 0002-9513
PB American Physiological Society
DT Journal; General Review
LA English
RE.CNT 105 THERE ARE 105 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:159659 CAPLUS
DN 133:53000
TI Imidazoline receptor agonist drugs for treatment of systemic hypertension
and congestive heart failure
AU Palkhiwala, Sameet A.; Yu, Austin; Frishman, William H.
CS Department of Medicine, Westchester Medical Center, New York Medical
College, Valhalla, NY, 10595, USA
SO Heart Disease (2000), 2(1), 83-92
CODEN: HTDSFE; ISSN: 1521-737X
PB Lippincott Williams & Wilkins
DT Journal; General Review
LA English
RE.CNT 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:90565 CAPLUS
DN 132:259984
TI Clinical and molecular pharmacology of .alpha.2-
adrenergic receptors: novel insight from transgenic
animal models
AU Hein, L.
CS Department of Pharmacology and Toxicology, University of Wurzburg, Germany

SO Klinische Pharmakologie (1999), 19(Prediction of Clinical Drug Actions
from In-vitro Approaches--Fact or Fiction?), 25-29
CODEN: KLPHEH; ISSN: 0937-0978
PB W. Zuckschwerdt Verlag GmbH
DT Journal; General Review
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:632696 CAPLUS
DN 130:85
TI New approaches to rapid-onset antidepressants
AU Briner, Karin; Dodel, Richard C.
CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN,
46285, USA
SO Current Pharmaceutical Design (1998), 4(4), 291-302
CODEN: CPDEFP; ISSN: 1381-6128
PB Bentham Science Publishers
DT Journal; General Review
LA English
RE.CNT 146 THERE ARE 146 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:39944 CAPLUS
DN 128:162456
TI Mirtazapine, an antidepressant
AU Puzantian, Talia
CS Clin. Pharm. Psychiatry, San Francisco Gen. Hosp., San Francisco, CA, USA
SO American Journal of Health-System Pharmacy (1998), 55(1), 44-49
CODEN: AHSPEK; ISSN: 1079-2082
PB American Society of Health-System Pharmacists
DT Journal; General Review
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1997:104627 CAPLUS
DN 126:139957
TI Adrenaline receptor and dopamine receptor
AU Kurose, Hitoshi
CS Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan
SO Tanpakushitsu Kakusan Koso (1997), 42(3), 316-326
CODEN: TAKKAJ; ISSN: 0039-9450
PB Kyoritsu
DT Journal; General Review
LA Japanese

L8 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:745710 CAPLUS
DN 126:83861
TI .alpha.2 Receptor and antidepressant
AU Sugita, Rintaro; Sekiya, Yukari; Terada, Kyoko; Sawa, Yutaka; Nomura,
Soichiro
CS Toyota Meml. Hosp., Toyota Motor Corp., Toyota, 471, Japan
SO Kekkan to Naihi (1996), 6(6), 663-669
CODEN: KENAE5; ISSN: 0917-5318
PB Medikaru Rebyusha
DT Journal; General Review
LA Japanese

L8 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1996:502266 CAPLUS
 DN 125:157516
 TI Clonidine: A critical review of its role in the treatment of
 psychiatric disorders
 AU Ahmed, Iqbal; Takeshita, Junji
 CS Hawaii State Hospital, University Hawaii, Kaneohe, HI, USA
 SO CNS Drugs (1996), 6(1), 53-70
 CODEN: CNDREF; ISSN: 1172-7047
 PB Adis
 DT Journal; General Review
 LA English

L8 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1996:432649 CAPLUS
 DN 125:75141
 TI What future for antidepressants
 AU Bourin, M.; Malinge, M.; Guitton, B.
 CS Faculte de Medecine, GIS Medicament, NANTES, 44035, Fr.
 SO Saudi Pharmaceutical Journal (1996), 4(2), 63-68
 CODEN: SPJOEM; ISSN: 1319-0164
 PB Saudi Pharmaceutical Society
 DT Journal; General Review
 LA English

L8 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1995:877604 CAPLUS
 DN 124:26675
 TI Involvement of I1-imidazoline receptors in mood disorders
 AU Piletz, John E.; Halaris, Angelos
 CS Medical Center, University Mississippi, Jackson, MS, 39216-4505, USA
 SO Annals of the New York Academy of Sciences (1995), 763(Imidazoline
 Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and
 Medicine), 510-19
 CODEN: ANYAA9; ISSN: 0077-8923
 PB New York Academy of Sciences
 DT Journal; General Review
 LA English

=> d his

(FILE 'HOME' ENTERED AT 13:42:54 ON 26 FEB 2008)

FILE 'CAPLUS' ENTERED AT 13:43:05 ON 26 FEB 2008

L1 0 S HALPHA2 RECEPTORS
 L2 0 S H-ALPHA-2 RECEPTORS
 L3 39489 S RECEPTORS AND ADRENERGIC
 L4 22726 S L3 AND ALPHA
 L5 14228 S L4 AND 2
 L6 8598 S L3 AND (ALPHA WITH 2)
 L7 473 S L6 AND REVIEW
 L8 44 S L7 AND (DEPRESSION OR ANXIETY OR MOVEMENT OR PSYCHOSIS OR WEI
 L9 44 S L8

FILE 'STNGUIDE' ENTERED AT 13:46:57 ON 26 FEB 2008

FILE 'CAPLUS' ENTERED AT 13:47:12 ON 26 FEB 2008

FILE 'STNGUIDE' ENTERED AT 13:47:13 ON 26 FEB 2008

FILE 'CAPLUS' ENTERED AT 14:07:24 ON 26 FEB 2008

FILE 'STNGUIDE' ENTERED AT 14:07:25 ON 26 FEB 2008

FILE 'CAPLUS' ENTERED AT 14:14:05 ON 26 FEB 2008

FILE 'STNGUIDE' ENTERED AT 14:14:06 ON 26 FEB 2008

=> d 18 30 -44

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L8 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1995:877604 CAPLUS
DN 124:26675
TI Involvement of I1-imidazoline receptors in mood disorders
AU Piletz, John E.; Halaris, Angelos
CS Medical Center, University Mississippi, Jackson, MS, 39216-4505, USA
SO Annals of the New York Academy of Sciences (1995), 763(Imidazoline
Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and
Medicine), 510-19
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal; General Review
LA English

L8 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1353951 CAPLUS
TI Agmatine metabolic pathway and spectrum of activity in brain
AU Halaris, Angelos; Plietz, John
CS Department of Psychiatry and Behavioral Neurosciences, Loyola University
Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA
SO CNS Drugs (2007), 21(11), 885-900
CODEN: CNDREF; ISSN: 1172-7047
PB Wolters Kluwer Health
DT Journal; General Review
LA English

L8 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:994117 CAPLUS
DN 147:419078
TI Duloxetine. A review of its use in the treatment of major
depressive disorder
AU Frampton, James E.; Plosker, Greg L.
CS Wolters Kluwer Health | Adis, Auckland, N. Z.
SO CNS Drugs (2007), 21(7), 581-609
CODEN: CNDREF; ISSN: 1172-7047
PB Wolters Kluwer Health
DT Journal; General Review
LA English

RE.CNT 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1039299 CAPLUS
DN 147:22182
TI New pharmacologic horizons in the treatment of Parkinson disease
AU Bonuccelli, Ubaldo; Del Dotto, Paolo
CS Department of Neurocience, University of Pisa and Neurology Unit, Pisa,
Italy

SO Neurology (2006), 67(7, Suppl. 2), S30-S38
CODEN: NEURAI; ISSN: 0028-3878
PB Lippincott Williams & Wilkins
DT Journal; General Review
LA English
RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:984781 CAPLUS
DN 146:513215
TI Genetics of antipsychotic treatment emergent weight gain in
schizophrenia
AU Mueller, Daniel J.; Kennedy, James L.
CS Department of Psychiatry, Charite University Medicine Berlin, Berlin,
10559, Germany
SO Pharmacogenomics (2006), 7(6), 863-887
CODEN: PARMFL; ISSN: 1462-2416
PB Future Medicine Ltd.
DT Journal; General Review
LA English
RE.CNT 180 THERE ARE 180 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:173864 CAPLUS
DN 145:158696
TI The effects of serotonin uptake inhibitors on platelet serotonin: from
basic to clinical research
AU Muck-Seler, Dorotea; Pivac, Nela; Sagud, Marina; Mustapic, Maja;
Jakovljevic, Miro
CS Rudjer Boskovic Institute, Zagreb, Croatia
SO Trends in Serotonin Uptake Inhibitor Research (2005), 29-53. Editor(s):
Shirley, Anne C. Publisher: Nova Science Publishers, Inc., Hauppauge, N.
Y.
CODEN: 69HVPE; ISBN: 1-59454-338-0
DT Conference; General Review
LA English
RE.CNT 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:107038 CAPLUS
DN 145:55182
TI Drugs in development for Parkinson's disease: an update
AU Johnston, Tom H.; Brotchie, Jonathan M.
CS Toronto Western Research Institute Toronto Western Hospital, University
Health Network, Toronto, ON, M5T 2S8, Can.
SO Current Opinion in Investigational Drugs (Thomson Scientific) (2005),
Volume Date 2006, 7(1), 25-32
CODEN: COIDAZ; ISSN: 1472-4472
PB Thomson Scientific
DT Journal; General Review
LA English
RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1050229 CAPLUS
DN 143:359326
TI α 1-Adrenoceptors as potential therapeutic targets
AU Sarma, P. K. S.; Tiwari, Atul; Pal, Arani

CS Department of Medicinal Chemistry-NDDR, Ranbaxy Research Laboratories,
Gurgaon(Haryana), 122001, India
SO Expert Opinion on Therapeutic Patents (2005), 15(10), 1333-1351
CODEN: EOTPEG; ISSN: 1354-3776
PB Ashley Publications Ltd.
DT Journal; General Review
LA English

RE.CNT 136 THERE ARE 136 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1040300 CAPLUS
DN 144:184743
TI Does the panic attack activate the hypothalamic-pituitary-adrenal axis?
AU Graeff, Frederico G.; Garcia-Leal, Cybele; Del-Ben, Cristina M.;
Guimaraes, Francisco S.
CS Departamento de Neurologia, Psiquiatria e Psicologia Medica, Hospital das
Clinicas da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao
Paulo, Ribeirao Preto, SP, 14048-900, Brazil
SO Anais da Academia Brasileira de Ciencias (2005), 77(3), 477-491
CODEN: AABCAD; ISSN: 0001-3765
PB Academia Brasileira de Ciencias
DT Journal; General Review
LA English

RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:662977 CAPLUS
DN 143:378838
TI Risperidone. A review of its use in the treatment of bipolar
mania
AU Fenton, Caroline; Scott, Lesley J.
CS Adis International Limited, Auckland, N. Z.
SO CNS Drugs (2005), 19(5), 429-444
CODEN: CNDREF; ISSN: 1172-7047
PB Adis International Ltd.
DT Journal; General Review
LA English

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:479092 CAPLUS
DN 143:125559
TI Novel pharmacological strategies for motor complications in
Parkinson's disease
AU Konitsiotis, Spiros
CS Department of Neurology, University of Ioannian Medical School, Ioannina,
GR-45110, Greece
SO Expert Opinion on Investigational Drugs (2005), 14(4), 377-392
CODEN: EOIDER; ISSN: 1354-3784
PB Ashley Publications Ltd.
DT Journal; General Review
LA English

RE.CNT 155 THERE ARE 155 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:275002 CAPLUS
DN 143:319199
TI Pathophysiology of Parkinson's disease, neurochemical pathology:

other neurotransmitters
AU Mizuno, Yoshikuni
CS Department of Neurology, Juntendo University School of Medicine, Tokyo,
Japan
SO Parkinson's Disease (2005), 443-477. Editor(s): Ebadi, Manuchair;
Pfeiffer, Ronald E. Publisher: CRC Press LLC, Boca Raton, Fla.
CODEN: 69GSAJ; ISBN: 0-8493-1590-5
DT Conference; General Review
LA English
RE.CNT 220 THERE ARE 220 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:249222 CAPLUS
DN 143:70724
TI CNS targets for multi-functional drugs in the treatment of Alzheimer's and
Parkinson's diseases
AU Youdim, M. B. H.; Buccafusco, J. J.
CS Technion-Rappaport Family-Faculty of Medicine, Eve Topf and US National
Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases,
Haifa, Israel
SO Journal of Neural Transmission (2005), 112(4), 519-537
CODEN: JNTRF3; ISSN: 0300-9564
PB Springer Wien
DT Journal; General Review
LA English
RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:320196 CAPLUS
DN 141:86353
TI Central monoamines and their role in major depression
AU Elhwuegi, Abdalla Salem
CS Faculty of Pharmacy and Health Sciences, Department of Pharmacology and
Toxicology, Ajman University of Science and Technology (AUST) Network, Abu
Dhabi, United Arab Emirates
SO Progress in Neuro-Psychopharmacology & Biological Psychiatry (2004),
28(3), 435-451
CODEN: PNPPD7; ISSN: 0278-5846
PB Elsevier Science B.V.
DT Journal; General Review
LA English
RE.CNT 147 THERE ARE 147 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:157387 CAPLUS
DN 139:239380
TI Duloxetine Eli Lilly
AU Anttila, Sami; Leinonen, Esa
CS Department of Psychogeriatrics, Tampere University Hospital, Pitkaniemi,
FIN-33380, Finland
SO Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2002), 3(8),
1217-1221
CODEN: COIDAZ; ISSN: 1472-4472
PB PharmaPress Ltd.
DT Journal; General Review
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:151546 CAPLUS
DN 139:46227
TI New approaches in the treatment of overactive bladder: Targeting
adrenergic receptors and neurokinin receptors
AU Ishizuka, O.
CS Department of Urology, Shinshu University School of Medicine, Matsumoto,
390-8621, Japan
SO Current Medicinal Chemistry: Central Nervous System Agents (2003), 3(1),
43-47
CODEN: CMCCCO; ISSN: 1568-0150
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:836902 CAPLUS
DN 138:150965
TI Psychiatric disorders
AU Gurguis, George N. M.; Rush, A. John
CS Department of Psychiatry, Dallas Veterans Administration Medical Center
and University of Texas Southwestern Medical Center, Dallas, TX, USA
SO Platelets (2002), 513-537. Editor(s): Michelson, Alan D. Publisher:
Academic Press, San Diego, Calif.
CODEN: 69DFK9; ISBN: 0-12-493951-1
DT Conference; General Review
LA English
RE.CNT 449 THERE ARE 449 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:50205 CAPLUS
DN 137:118858
TI A review of the pharmacological and clinical profile of
mirtazapine
AU Anttila, Sami A. K.; Leinonen, Esa V. J.
CS Ikaalinen Mental Health Center, Department of Psychiatry, Tampere
University Hospital, FIN-33380, Finland
SO CNS Drug Reviews (2001), 7(3), 249-264
CODEN: CDREFB; ISSN: 1080-563X
PB Neva Press
DT Journal; General Review
LA English
RE.CNT 103 THERE ARE 103 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:782179 CAPLUS
DN 136:128417
TI Antidepressant pharmacotherapy
AU Retamal C., Pedro
CS Departamento de Psiquiatria, Facultad de Medicina, Universidad de Chile,
Santiago de Chile, Chile
SO Revista Medica de Chile (2001), 129(7), 813-818
CODEN: RMCHAW; ISSN: 0034-9887
PB Sociedad Medica de Santiago
DT Journal; General Review
LA Spanish
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:554359 CAPLUS
DN 136:132382
TI Clinical and molecular genetics of ADHD and Tourette syndrome: Two related polygenic disorders
AU Comings, David E.
CS Department of Medical Genetics, City of Hope Medical Center, Duarte, CA, 91010, USA
SO Annals of the New York Academy of Sciences (2001), 931(Adult Attention Deficit Disorder), 50-83
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal; General Review
LA English
RE.CNT 218 THERE ARE 218 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:120294 CAPLUS
DN 134:217258
TI Review: reticuloruminal motility - a pharmacological target with a difference?
AU Leek, B. F.
CS Department of Veterinary Physiology & Biochemistry, University College Dublin, Dublin, Ire.
SO Veterinary Quarterly (2001), 23(1), 26-31
CODEN: VEQUDU; ISSN: 0165-2176
PB Royal Netherlands Veterinary Association
DT Journal; General Review
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:468525 CAPLUS
DN 133:175238
TI Mechanisms regulating hypoxic respiratory depression during fetal and postnatal life
AU Bissonnette, John M.
CS Departments of Obstetrics and Gynecology and Cell and Developmental Biology, Oregon Health Sciences University, Portland, OR, 97201-3098, USA
SO American Journal of Physiology (2000), 278(6, Pt. 2), R1391-R1400
CODEN: AJPHAP; ISSN: 0002-9513
PB American Physiological Society
DT Journal; General Review
LA English
RE.CNT 105 THERE ARE 105 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2000:159659 CAPLUS
DN 133:53000
TI Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure
AU Palkhiwala, Sameet A.; Yu, Austin; Frishman, William H.
CS Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, 10595, USA
SO Heart Disease (2000), 2(1), 83-92
CODEN: HTDSFE; ISSN: 1521-737X
PB Lippincott Williams & Wilkins
DT Journal; General Review

LA English

RE.CNT 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:90565 CAPLUS

DN 132:259984

TI Clinical and molecular pharmacology of .alpha.2-
adrenergic receptors: novel insight from transgenic
animal models

AU Hein, L.

CS Department of Pharmacology and Toxicology, University of Wurzburg, Germany

SO Klinische Pharmakologie (1999), 19(Prediction of Clinical Drug Actions
from In-vitro Approaches--Fact or Fiction?), 25-29

CODEN: KLPHEH; ISSN: 0937-0978

PB W. Zuckschwerdt Verlag GmbH

DT Journal; General Review

LA English

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:632696 CAPLUS

DN 130:85

TI New approaches to rapid-onset antidepressants

AU Briner, Karin; Dodel, Richard C.

CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN,
46285, USA

SO Current Pharmaceutical Design (1998), 4(4), 291-302

CODEN: CPDEFP; ISSN: 1381-6128

PB Bentham Science Publishers

DT Journal; General Review

LA English

RE.CNT 146 THERE ARE 146 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:39944 CAPLUS

DN 128:162456

TI Mirtazapine, an antidepressant

AU Puzantian, Talia

CS Clin. Pharm. Psychiatry, San Francisco Gen. Hosp., San Francisco, CA, USA

SO American Journal of Health-System Pharmacy (1998), 55(1), 44-49

CODEN: AHSPEK; ISSN: 1079-2082

PB American Society of Health-System Pharmacists

DT Journal; General Review

LA English

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:104627 CAPLUS

DN 126:139957

TI Adrenaline receptor and dopamine receptor

AU Kurose, Hitoshi

CS Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan

SO Tanpakushitsu Kakusan Koso (1997), 42(3), 316-326

CODEN: TAKKAJ; ISSN: 0039-9450

PB Kyoritsu

DT Journal; General Review

LA Japanese

L8 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1996:745710 CAPLUS
 DN 126:83861
 TI .alpha.2 Receptor and antidepressant
 AU Sugita, Rintaro; Sekiya, Yukari; Terada, Kyoko; Sawa, Yutaka; Nomura, Soichiro
 CS Toyota Meml. Hosp., Toyota Motor Corp., Toyota, 471, Japan
 SO Kekkan to Naihi (1996), 6(6), 663-669
 CODEN: KENAE5; ISSN: 0917-5318
 PB Medikaru Rebyusha
 DT Journal; General Review
 LA Japanese

L8 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1996:502266 CAPLUS
 DN 125:157516
 TI Clonidine: A critical review of its role in the treatment of psychiatric disorders
 AU Ahmed, Iqbal; Takeshita, Junji
 CS Hawaii State Hospital, University Hawaii, Kaneohe, HI, USA
 SO CNS Drugs (1996), 6(1), 53-70
 CODEN: CNDREF; ISSN: 1172-7047
 PB Adis
 DT Journal; General Review
 LA English

L8 ANSWER 29 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1996:432649 CAPLUS
 DN 125:75141
 TI What future for antidepressants
 AU Bourin, M.; Malinge, M.; Guitton, B.
 CS Faculte de Medecine, GIS Medicament, NANTES, 44035, Fr.
 SO Saudi Pharmaceutical Journal (1996), 4(2), 63-68
 CODEN: SPJOEM; ISSN: 1319-0164
 PB Saudi Pharmaceutical Society
 DT Journal; General Review
 LA English

L8 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1995:877604 CAPLUS
 DN 124:26675
 TI Involvement of 11-imidazoline receptors in mood disorders
 AU Piletz, John E.; Halaris, Angelos
 CS Medical Center, University Mississippi, Jackson, MS, 39216-4505, USA
 SO Annals of the New York Academy of Sciences (1995), 763(Imidazoline Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and Medicine), 510-19
 CODEN: ANYAA9; ISSN: 0077-8923
 PB New York Academy of Sciences
 DT Journal; General Review
 LA English

L8 ANSWER 31 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1995:743369 CAPLUS
 DN 123:159855
 TI The selective .alpha.2-adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission
 AU de Boer, Thijs; Ruigt, Ge S.F.
 CS Neuropharmacology Department, N.V. Organon, Oss, Neth.
 SO CNS Drugs (1995), 4(1), 29-38
 CODEN: CNDREF; ISSN: 1172-7047

PB Adis
DT Journal; General Review
LA English

L8 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:235207 CAPLUS
DN 120:235207
TI Medetomidine - a new selective alpha2-adrenoceptor agonist
AU Venkataraman, B. V.; Rani, M. A. Naga
CS Dep. Pharmacol., St.John's Med. Coll., Bangalore, 560 034, India
SO Indian Journal of Pharmacology (1993), 25(4), 188-92
CODEN: INJPD2; ISSN: 0253-7613
DT Journal; General Review
LA English

L8 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1993:492315 CAPLUS
DN 119:92315
TI Platelet .alpha.2-adrenoreceptors in
depression: a critical examination
AU Grossman, Fred; Manji, Hussein K.; Potter, William Z.
CS Exp. Ther. Branch, Natl. Inst. Ment. Health, Bethesda, MD, 20892, USA
SO Journal of Psychopharmacology (London, United Kingdom) (1993), 7(1), 4-18
CODEN: JOPSEQ; ISSN: 0269-8811
DT Journal; General Review
LA English

L8 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:420796 CAPLUS
DN 117:20796
TI Evidence for hypothalamo-growth hormone dysfunction in panic disorder:
profile of growth hormone (GH) responses to clonidine, yohimbine,
caffeine, glucose, GRF and TRH in panic disorder patients versus healthy
volunteers
AU Uhde, Thomas W.; Tancer, Manuel E.; Rubinow, David R.; Roscow, Diana B.;
Boulenger, Jean Philippe; Vittone, Bernard; Gurguis, George; Geraci,
Marilla; Black, Bruce; Post, Robert M.
CS Sect. Anxiety Affective Disord., Natl. Inst. Ment. Health, Bethesda, MD,
20892, USA
SO Neuropsychopharmacology (1992), 6(2), 101-18
CODEN: NEROEW; ISSN: 0893-133X
DT Journal
LA English

L8 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1991:556032 CAPLUS
DN 115:156032
TI The alpha-2 adrenoceptor vulnerability hypothesis of
depression: from the clonidine growth hormone stimulation test to
the genes encoding a human alpha-2 adrenoceptor and
phenylethanolamine N-methyltransferase
AU Hoehe, M. R.; Goldin, L. R.; Baetge, E. E.; Lentjes, K. U.; Berrettini, W.
H.
CS Clin. Neurogenet. Branch, NIMH, Bethesda, MD, 20892, USA
SO Neuropsychopharmacol., Proc. C.I.N.P. Congr., 16th (1990), Meeting Date
1988, Volume 1, 70-83. Editor(s): Bunney, William E. Publisher: Springer,
Berlin, Fed. Rep. Ger.
CODEN: 57EBAZ
DT Conference; General Review
LA English

L8 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1990:195998 CAPLUS
 DN 112:195998
 TI Peripheral adrenergic receptors in affective illness
 and schizophrenia
 AU Pandey, Ghanshyam N.; Pandey, Subhash C.; Davis, John M.
 CS Coll. Med., Univ. Illinois, Chicago, IL, 60612, USA
 SO Pharmacology & Toxicology (Oxford, United Kingdom) (1990), 66(Suppl. 3),
 13-36
 CODEN: PHTOEH; ISSN: 0901-9928
 DT Journal; General Review
 LA English

L8 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1989:592339 CAPLUS
 DN 111:192339
 TI Platelet and brain .alpha.2-adrenoceptors in
 endogenous depression
 AU Garcia-Sevilla, Jesus A.
 CS Fac. Med., Univ. Basque Ctry., Lejona, E-48940, Spain
 SO International Congress Series (1989), 839(Recent Adv. Pharmacol. Ther.),
 421-3
 CODEN: EXMDA4; ISSN: 0531-5131
 DT Journal; General Review
 LA English

L8 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1989:494649 CAPLUS
 DN 111:94649
 TI Neurochemical and electrophysiological events underlying stress-induced
 depression in an animal model
 AU Weiss, Jay M.; Simson, Peter E.
 CS Med. Cent., Duke Univ., Durham, NC, 27710, USA
 SO Advances in Experimental Medicine and Biology (1988), 245(Mech. Phys.
 Emotional Stress), 425-40
 CODEN: AEMBAP; ISSN: 0065-2598
 DT Journal; General Review
 LA English

L8 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1989:5405 CAPLUS
 DN 110:5405
 TI Noradrenergic and serotonergic receptor system function in panic disorder
 and depression
 AU Heninger, G. R.; Charney, D. S.; Price, L. H.
 CS Sch. Med., Yale Univ., New Haven, CT, USA
 SO Acta Psychiatrica Scandinavica, Supplementum (1988), 341, 138-50
 CODEN: ASSUA6; ISSN: 0065-1591
 DT Journal; General Review
 LA English

L8 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1987:207533 CAPLUS
 DN 106:207533
 TI Glucocorticoid-induced changes in central opiate and adrenergic
 mechanisms
 AU Fekete, M. I. K.; Kanyicska, B.; Szentendrei, T.
 CS Inst. Exp. Med., Hung. Acad. Sci., Budapest, Hung.
 SO Adv. Pharmacol. Res. Pract., Proc. Congr. Hung. Pharmacol. Soc., 4th
 (1986), Meeting Date 1985, Volume 2, 277-84. Editor(s): Knoll, Jozsef;
 Kelemen, Karoly. Publisher: Pergamon, Oxford, UK.
 CODEN: 55NPA6
 DT Conference; General Review

LA English

L8 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1986:606990 CAPLUS

DN 105:206990

OREF 105:33356h,33357a

TI Evaluation of studies on platelet alpha2 adrenoreceptors in depressive illness

AU Piletz, John E.; Schubert, Daniel S. P.; Halaris, Angelos

CS Dep. Psychiatry, Case West. Reserve Univ., Cleveland, OH, 44109, USA

SO Life Sciences (1986), 39(18), 1589-616

CODEN: LIFSAK; ISSN: 0024-3205

DT Journal; General Review

LA English

L8 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1986:102533 CAPLUS

DN 104:102533

OREF 104:16087a,16090a

TI Platelet .alpha.2-adrenergic receptors in depression

AU Kafka, Marian S.; Paul, Steven M.

CS Clin. Neurosci. Branch, Natl. Inst. Ment. Health, Bethesda, MD, 20892, USA

SO Archives of General Psychiatry (1986), 43(1), 91-5

CODEN: ARGPAQ; ISSN: 0003-990X

DT Journal; General Review

LA English

L8 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1984:504146 CAPLUS

DN 101:104146

OREF 101:15769a,15772a

TI Depression, .alpha.2-receptors and sex hormones: neuroendocrine studies in rat

AU Eriksson, Elias; Modigh, Kjell

CS Dep. Pharmacol., Univ. Goeteborg, Goeteborg, S-400 33, Swed.

SO Advances in Biochemical Psychopharmacology (1984), 39(Front. Biochem. Pharmacol. Res. Depression), 161-78

CODEN: ABPYBL; ISSN: 0065-2229

DT Journal; General Review

LA English

L8 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1981:580383 CAPLUS

DN 95:180383

OREF 95:29947a,29950a

TI Comparison of α -adrenoceptors at peripheral and central cardiovascular sites

AU Kobinger, Walter

CS Pharmacol. Dep., Ernst Boehringer Inst. Drug Res., Vienna, A-1121, Austria

SO Perspectives in Cardiovascular Research (1981), 6(Cent. Nerv. Syst. Mech. Hypertens.), 171-8

CODEN: PCRED9; ISSN: 0361-0527

DT Journal; General Review

LA English

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	32	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	33	JUN 30	STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:11:08 ON 17 JUL 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:11:19 ON 17 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 JUL 2008 HIGHEST RN 1034374-44-1
DICTIONARY FILE UPDATES: 16 JUL 2008 HIGHEST RN 1034374-44-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10524989.str



```

chain nodes :
14 15 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13
chain bonds :
13-14 14-15 15-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13
exact/norm bonds :
5-7 6-10 7-8 7-11 8-9 8-13 9-10 11-12 12-13 13-14 14-15 15-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

G1:C,O,S,N

G2:C,H,O,S,N,NH,NH2,NH3,X,Cb,Cy,Hy,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 21:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 C, O, S, N

G2 C, H, O, S, N, NH, NH2, NH3, X, Cb, Cy, Hy, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

FULL SEARCH INITIATED 12:11:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 14675 TO ITERATE

100.0% PROCESSED 14675 ITERATIONS

672 ANSWERS

SEARCH TIME: 00.00.01

L2 672 SEA SSS FUL L1

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 12:11:41 ON 17 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2008 VOL 149 ISS 3

FILE LAST UPDATED: 16 Jul 2008 (20080716/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12

L3 21 L2

=> d 13 1-21 ibib hitstr

L3 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:474148 CAPLUS

DOCUMENT NUMBER: 146:492615

TITLE: Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α 2-adrenoceptor antagonism

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H.; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Drinkenburg, Wilhelmus; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Langlois, Xavier; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor, Joaquin; Pullan, Shirley; Steckler, Thomas

CORPORATE SOURCE: Research & Early Development-EU, CNS-Psychiatry, Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain

SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(11), 3649-3660

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:492615

IT 452313-46-1P 452313-65-4P 452313-68-7P

452313-71-2P 452314-01-1P 452318-73-9P

452318-75-1P 722545-47-3P 936362-34-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α 2-adrenoceptor antagonism)

RN 452313-46-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)-(CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.


Double bond geometry as shown.



RN 452313-65-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-68-7 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452314-01-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-75-1 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 722545-47-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 936362-34-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.



IT 452313-36-9 452318-26-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α 2-adrenoceptor antagonism)
 RN 452313-36-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 936362-26-4P 936362-28-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α 2-adrenoceptor antagonism)

RN 936362-26-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 936362-28-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:896726 CAPLUS

DOCUMENT NUMBER: 145:419002

TITLE: Synthesis of isoxazole-5-carboxylates by cyclization of oxime 1,4-dianions with diethyl oxalate

AUTHOR(S): Dang, Tuan Thanh; Albrecht, Uwe; Langer, Peter

CORPORATE SOURCE: Institut fuer Chemie, Universitaet Rostock, Rostock, 18059, Germany

SOURCE: Synthesis (2006), (15), 2515-2522

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:419002


IT 912347-87-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of isoxazolecarboxylates by cyclization of oxime dianions with oxalate)

RN 912347-87-6 CAPLUS

CN Naphth[1,2-c]isoxazole-3-carboxylic acid, 3,3a,4,5-tetrahydro-3-hydroxy-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:511158 CAPLUS

DOCUMENT NUMBER: 145:27976

TITLE: Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic activity

INVENTOR(S): Andres-Gil, Jose Ignacio; Bartolome-Nebreda, Jose Manuel; Alcazar-Vaca, Manuel Jesus; Garcia-Martin, Maria de las Mercedes; Megens, Antonius Adrianus Hendrikus Petrus

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056600	A1	20060601	WO 2005-EP56229	20051125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005308778	A1	20060601	AU 2005-308778	20051125
CA 2585857	A1	20060601	CA 2005-2585857	20051125
EP 1819713	A1	20070822	EP 2005-816247	20051125
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101084225	A	20071205	CN 2005-80040127	20051125
JP 2008521771	T	20080626	JP 2007-541989	20051125
US 20080113988	A1	20080515	US 2007-791510	20070524
PRIORITY APPLN. INFO.:			EP 2004-106123	A 20041126
			WO 2005-EP56229	W 20051125

OTHER SOURCE(S): MARPAT 145:27976

IT 888727-62-6P 888727-63-7P 888728-09-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)

RN 888727-62-6 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 888727-63-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, N-[3-(5-fluoro-1H-indol-3-yl)propyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 888728-09-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-fluoro-1H-indol-3-yl)methyl]-1-piperidinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 888728-14-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of isoxazoline-indole derivs. with antipsychotic and anxiolytic activity)
 RN 888728-14-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanol, 7-bromo-3a,4-dihydro-, 3-propanoate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:505909 CAPLUS
DOCUMENT NUMBER: 145:95782
TITLE: Synthesis of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivatives displaying combined α 2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities
AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; De Lucas, Ana I.; Iturrino, Laura; Biesmans, Ilse; Megens, Anton A.
CORPORATE SOURCE: Medicinal Chemistry Department, Division of Janssen-Cilag, Johnson & Johnson Pharmaceutical Research and Development, Toledo, 45007, Spain
SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(13), 4361-4372
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:95782
IT 612074-52-9P 612074-56-3P 612074-57-4P
612074-68-7P 612074-81-4P 612074-88-1P
612074-89-2P 612074-90-5P 612074-92-7P
612074-93-8P 612074-94-9P 612074-95-0P
612074-98-3P 612074-99-4P 612075-02-2P
612075-03-3P 612075-07-7P 612075-09-9P
612075-10-2P 612075-11-3P 612075-12-4P
612075-13-5P 612075-15-7P 612075-88-4P
770707-27-2P 895169-63-8P 895169-64-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzopyranoisoxazole derivs. displaying combined α 2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)
RN 612074-52-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-56-3 CAPLUS

CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-57-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3,4-dimethoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-68-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-81-4 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-88-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-89-2 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-90-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612074-92-7 CAPLUS
 CN Benzonitrile, 3-[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-93-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-94-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-95-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-98-3 CAPLUS

CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2,2-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-99-4 CAPLUS

CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-02-2 CAPLUS

CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-03-3 CAPLUS

CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-07-7 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-09-9 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-10-2 CAPLUS

CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-11-3 CAPLUS

CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-12-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-13-5 CAPLUS


CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-15-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-88-4 CAPLUS
 CN 1,2-Ethanedi-amine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 770707-27-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 895169-63-8 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 895169-64-9 CAPLUS

CN Ethanol, 2-[[[(3S,3aR)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 452318-26-2 452319-41-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(benzopyranoisoxazole derivs. displaying combined α 2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)

RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-


(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-41-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 452319-29-8P 612074-55-2P 612075-92-0P
895169-59-2P 895169-62-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzopyranoisoxazole derivs. displaying combined α 2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities)
RN 452319-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-55-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-92-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 7-fluoro-3a,4-dihydro-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 895169-59-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 7-bromo-3a,4-dihydro-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 895169-62-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:920735 CAPLUS

DOCUMENT NUMBER: 142:219240

TITLE: Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α 2-Adrenoceptor Blocking Activity

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.; Alvarez, Rosa M.; Bakker, Margot H.; Biesmans, Ilse; Cid, Jose M.; De Lucas, Ana I.; Fernandez, Javier; Font, Luis M.; Hens, Koen A.; Iturrino, Laura; Lenaerts, Ilse; Martinez, Sonia; Megens, Anton A.; Pastor, Joaquin; Vermote, Patrick C. M.; Steckler, Thomas

CORPORATE SOURCE: Johnson Johnson Pharmaceutical Research Development Division of Janssen-Cilag Medicinal Chemistry dept., Jarama s/n, Toledo, 45007, Spain

SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 2054-2071

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:219240

IT 452313-54-1P 452318-20-6P 452318-95-5P 608146-13-0P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)

RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)-(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)-(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 608146-13-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)-(CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




IT 452319-41-4
 RL: PAC (Pharmacological activity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 (preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)
 RN 452319-41-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




IT 452313-65-4P 452319-33-4P 452320-36-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α 2-adrenoceptor blocking activity)
 RN 452313-65-4 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-33-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452320-36-4 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




IT 452313-36-9P 452313-59-6P 452313-77-8P
 452318-26-2P 452318-93-3P 452319-43-6P
 452319-55-0P 452319-57-2P 452319-59-4P
 452319-61-8P 452319-63-0P 452319-65-2P
 452319-67-4P 452319-69-6P 452319-71-0P
 452320-40-0P 452320-52-4P 452320-54-6P
 452320-60-4P 452320-62-6P 452320-64-8P
 452320-66-0P 452320-70-6P 452321-33-4P
 452321-35-6P 452321-37-8P 452321-39-0P
 452321-41-4P 789484-08-8P 815632-62-3P
 815632-63-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation of centrally active tricyclic isoxazoles combining 5-HT
reuptake inhibition with α 2-adrenoceptor blocking activity)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-
3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX
NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-59-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-
naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452313-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-
naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-43-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-55-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-


phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, 7-acetate, (3R,3aS)-rel-
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-57-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, 7-propanoate, (3R,3aS)-rel-
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-59-4 CAPLUS
CN Acetic acid, 2-methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS
CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-65-2 CAPLUS

CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-67-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-69-6 CAPLUS
 CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-71-0 CAPLUS
 CN Ethanamine, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452320-40-0 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452320-52-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-54-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-62-6 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-64-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-66-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-70-6 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-33-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-35-6 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-37-8 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452321-39-0 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-41-4 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 789484-08-8 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 815632-62-3 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 815632-63-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-[2-(2-ethoxyethoxy)ethoxy]-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 452313-56-3P 452318-24-0P 452318-97-7P
 608146-12-9P
 RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP
 (Preparation)
 (preparation of centrally active tricyclic isoxazoles combining 5-HT
 reuptake inhibition with α 2-adrenoceptor blocking activity)
 RN 452313-56-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-
 3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA
 INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
 Double bond geometry as shown.



RN 452318-24-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-
 2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)-
 (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
 Double bond geometry as shown.



RN 452318-97-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-

3-phenyl-2-buten-1-yl]-1-piperazinyl)methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 608146-12-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl)methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



IT 452321-82-3P 452322-05-3P 452322-19-9P
452322-21-3P 608146-04-9P 815632-58-7P
815632-59-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of centrally active tricyclic isoxazoles combining 5-HT reuptake inhibition with α_2 -adrenoceptor blocking activity)

RN 452321-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-05-3 CAPLUS

CN Isioxazolo[4,3-c]quinoline-3-carboxylic acid, 3,3a,4,5-tetrahydro-5-(2,2,2-trifluoroacetyl)-, methyl ester, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-19-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxy-5-(2,2,2-trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-21-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxyisioxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-04-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 815632-58-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydronaphth[1,2-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 815632-59-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7-methoxynaphth[1,2-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:760314 CAPLUS

DOCUMENT NUMBER: 141:384410

TITLE: A screening strategy for the development of enantiomeric separation methods in capillary electrophoresis

AUTHOR(S): Jimidar, M. Ilias; van Ael, Willy; van Nyen, Patrick; Peeters, Margot; Redlich, Dirk; de Smet, Maurits

CORPORATE SOURCE: Pharmaceutical Research & Development (J&J-PRD) A division of Janssen Pharmaceutica n.v., Global Analytical Development, Johnson and Johnson, Beerse, Belg.

SOURCE: Electrophoresis (2004), 25(16), 2772-2785

CODEN: ELCTDN; ISSN: 0173-0835

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 452318-73-9


RL: ANT (Analyte); ANST (Analytical study)

(screening strategy for development of enantiomeric separation methods in capillary electrophoresis)

RN 452318-73-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:362586 CAPLUS

DOCUMENT NUMBER: 141:123602
 TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α 2-adrenoceptor antagonistic activities. Part 2: Further exploration on the cinnamyl moiety
 AUTHOR(S): Pastor, Joaquin; Alcazar, Jesus; Alvarez, Rosa M.; Andres, J. Ignacio; Cid, Jose M.; De Lucas, Ana I.; Diaz, Adolfo; Fernandez, Javier; Font, Luis M.; Iturrino, Laura; Lafuente, Celia; Martinez, Sonia; Bakker, Margot H.; Biesmans, Ilse; Heylen, Lieve I.; Megens, Anton A.
 CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Toledo, 45007, Spain
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2917-2922
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:123602

IT 452313-36-9P 452313-85-8P 452316-95-9P
 452316-97-1P 452318-26-2P 452318-71-7P
 452318-73-9P 452318-77-3P 452318-83-1P
 452318-87-5P 452318-93-3P 452319-01-6P
 452319-03-8P 452319-07-2P 452319-09-4P
 452320-98-8P 452321-14-1P 452321-21-0P
 452321-29-8P 452321-31-2P 722545-47-3P
 722545-48-4P 722545-55-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α 2-adrenoceptor antagonists)
 RN 452313-36-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452313-85-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-95-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-97-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452318-26-2 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-77-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-87-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-

3-phenyl-2-buten-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-01-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-buten-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-03-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-07-2 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-09-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-98-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-14-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-21-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-29-8 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-31-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 722545-47-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 722545-48-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 722545-55-3 CAPLUS

CN Phenol, 4-[(1E)-3-[4-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-methyl-1-propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452321-85-6P 452321-97-0P 452321-99-2P

722545-56-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α 2-adrenoceptor antagonists)

RN 452321-85-6 CAPLUS

CN 2-Propanone, 1-[4-[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-97-0 CAPLUS

CN 1,2-Propanediol, 3-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-99-2 CAPLUS

CN 1-Piperazineacetaldehyde, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 722545-56-4 CAPLUS

CN Phosphonic acid, [2-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-2-oxoethyl]-, diethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 722545-57-5P 722545-58-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of 3-(4-cinnamyl-1-piperazinylmethyl)-3a,4-dihydro-3H-


[1]benzopyrano[4,3-c]isoxazoles as combined 5-HT uptake inhibitors and α 2-adrenoceptor antagonists)

RN 722545-57-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-penten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 722545-58-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3,3-diphenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:182890 CAPLUS

DOCUMENT NUMBER: 140:217631

TITLE: Preparation of fused heterocyclic isoxazoline derivatives as anti-depressants

INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus; Bartolome-Nebreda, Jose Manuel; Fernandez-Gadea, Francisco Javier; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018483	A1	20040304	WO 2003-EP50377	20030813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494557	A1	20040304	CA 2003-2494557	20030813
AU 2003262573	A1	20040311	AU 2003-262573	20030813
EP 1554286	A1	20050720	EP 2003-792431	20030813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1675224	A	20050928	CN 2003-819462	20030813
JP 2005538144	T	20051215	JP 2004-530272	20030813
US 20060116378	A1	20060601	US 2005-524123	20050210
PRIORITY APPLN. INFO.:			EP 2002-78373	A 20020815
			WO 2003-EP50377	W 20030813

OTHER SOURCE(S): MARPAT 140:217631


IT 666233-82-5P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-82-5 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




IT 666233-90-5P 666233-91-6P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-90-5 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 666233-91-6 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-ethanol,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 666233-75-6P 666233-84-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-75-6 CAPLUS

CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,7-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 666233-84-7 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole-7-acetic acid,
3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
piperazinyl]methyl]-, methyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 666233-76-7P 666233-77-8P 666233-78-9P
 666233-79-0P 666233-80-3P 666233-81-4P
 666233-83-6P 666233-85-8P 666233-86-9P
 666233-87-0P 666233-88-1P 666233-89-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of fused heterocyclic isoxazoline derivs. as antidepressants)

RN 666233-76-7 CAPLUS

CN 3H,4H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole, 3-[[4-[(2E)-3-(3-
 fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,7-dihydro-,
 (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 666233-77-8 CAPLUS

CN 3H,4H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole, 3-[[4-[(2E)-3-(4-
 fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,7-dihydro-,
 (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 666233-78-9 CAPLUS

CN 3H,4H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,7-dihydro-3-[[4-(2-
 naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 666233-79-0 CAPLUS

CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,7-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 666233-80-3 CAPLUS

CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,7-dihydro-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 666233-81-4 CAPLUS

CN 3H,4H-Isoxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,7-dihydro-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 666233-83-6 CAPLUS

CN 3H,4H-Isioxazolo[3',4':4,5]pyrano[3,2-f]indole, 3a,7-dihydro-7-[(2-methoxyethoxy)methyl]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 666233-85-8 CAPLUS

CN Ethanone, 1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-isoxazolo[3',4':4,5]pyrano[3,2-f]indol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 666233-86-9 CAPLUS


CN Methanone, cyclopropyl[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-isoxazolo[3',4':4,5]pyrano[3,2-f]indol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 666233-87-0 CAPLUS
 CN 3H,7H-Isioxazolo[3',4':4,5]pyrano[3,2-f]indole-7-carboxylic acid,
 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, methyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 666233-88-1 CAPLUS
 CN Ethanone, 1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-
 1-yl]-1-piperazinyl]methyl]-3H,7H-isioxazolo[3',4':4,5]pyrano[3,2-f]indol-7-
 yl]-2-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 666233-89-2 CAPLUS
 CN 3H,4H-Isioxazolo[3',4':4,5]pyrano[3,2-f]indole, 7-ethyl-3a,7-dihydro-3-[[4-
 [(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



IT 666234-10-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of fused heterocyclic isoxazoline derivs. as antidepressants)
 RN 666234-10-2 CAPLUS
 CN 3H,4H-Isloxazolo[3',4':4,5]pyrano[3,2-f]indole-3-carboxylic acid,
 7-(2,2-dimethyl-1-oxopropyl)-3a,7-dihydro-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:182889 CAPLUS
 DOCUMENT NUMBER: 140:235700
 TITLE: Preparation of chromenoisoxazole derivatives and their
 use as anti-depressants
 INVENTOR(S): Andres-Gil, Jose Ignacio; Alcazar-Vaca, Manuel Jesus;
 Matesanz-Ballesteros, Maria Encarnacion; Bakker,
 Margaretha Henrica Maria; Megens, Antonius Adrianus
 Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018482	A2	20040304	WO 2003-EP9532	20030819
WO 2004018482	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2495058 A1 20040304 CA 2003-2495058 20030819
 AU 2003271567 A1 20040311 AU 2003-271567 20030819
 EP 1532155 A2 20050525 EP 2003-753363 20030819
 EP 1532155 B1 20080227
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CN 1675223 A 20050928 CN 2003-819862 20030819
 JP 2005538143 T 20051215 JP 2004-530256 20030819
 AT 387455 T 20080315 AT 2003-753363 20030819
 ES 2301816 T3 20080701 ES 2003-753363 20030819
 US 20060122167 A1 20060608 US 2005-524989 20050218
 PRIORITY APPLN. INFO.: EP 2002-78844 A 20020821
 WO 2003-EP9532 W 20030819

OTHER SOURCE(S): MARPAT 140:235700

IT 667454-35-5P 667454-39-9P 667454-52-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of chromenoisoxazole derivs. as
 antidepressants)

RN 667454-35-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 6-bromo-3a,4-dihydro-7,8-dimethoxy-3-
 [[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
 (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 667454-39-9 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-6-methoxy-3-[[4-[(2E)-2-
 methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA
 INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 667454-52-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-6-iodo-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




IT 667454-36-6P 667454-37-7P 667454-38-8P
 667454-40-2P 667454-41-3P 667454-42-4P
 667454-43-5P 667454-44-6P 667454-45-7P
 667454-46-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of chromenoisoxazole derivs. as antidepressants)


RN 667454-36-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 6-(4-bromo-1-piperazinyl)-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 667454-37-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-6-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 667454-38-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-6-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 667454-40-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 667454-41-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-6-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-N-4-pyridinyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 667454-42-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-9-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 667454-43-5 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 667454-44-6 CAPLUS

CN Acetic acid, 2-methoxy-, 2-[[[(3S,3aR)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 667454-45-7 CAPLUS

CN Acetic acid, 2-methoxy-, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-6-yl]oxy]ethyl ester, rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 667454-46-8 CAPLUS

CN Carbamic acid, ethyl-, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-9-yl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT 452321-67-4P 667454-49-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of chromenoisoxazole derivs. as antidepressants)

RN 452321-67-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-, methyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 667454-49-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-6-methoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:162696 CAPLUS
 DOCUMENT NUMBER: 140:217662
 TITLE: Preparation of piperazinylalkylchromenoisoxazolines as antidepressants.
 INVENTOR(S): Andres-gil, Jose Ignacio; Bartolome-nebreda, Jose Manuel; Alvarez-escobar, Rosa Maria; Bakker, Margaretha Henrica Maria; Megens, Antonius Adrianus Hendrikus Petrus
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004016621	A1	20040226	WO 2003-EP50374	20030812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
CA 2494235	A1	20040226	CA 2003-2494235 20030812
AU 2003262571	A1	20040303	AU 2003-262571 20030812
EP 1537124	A1	20050608	EP 2003-787817 20030812
EP 1537124	B1	20070801	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
CN 1675222	A	20050928	CN 2003-819483 20030812
JP 2005537304	T	20051208	JP 2004-528523 20030812
AT 368669	T	20070815	AT 2003-787817 20030812
ES 2290537	T3	20080216	ES 2003-787817 20030812
US 20050256119	A1	20051117	US 2005-524197 20050210
PRIORITY APPLN. INFO.:			EP 2002-78322 A 20020812
			WO 2003-EP50374 W 20030812

OTHER SOURCE(S): MARPAT 140:217662

IT 452320-31-9P 663933-45-7P, 8-Methyl-3-[4-(3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-46-8P, 8-Methoxy-7-methyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-47-9P, [8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]methanol 663933-48-0P, 7-Methoxymethyl-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-49-1P 663933-50-4P 663933-51-5P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenoxyethyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-52-6P 663933-53-7P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-morpholin-4-ylmethyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-54-8P 663933-55-9P 663933-56-0P, 3-[4-(2-Methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carbonitrile 663933-57-1P 663933-58-2P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole-7-carboxylic acid ethylamide 663933-59-3P, 8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-7-phenyl-3a,4-dihydro-3H-chromeno[4,3-c]isoxazole 663933-60-6P, 1-[5-[8-Methoxy-3-[4-(2-methyl-3-phenylallyl)piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl]thiophen-2-yl]ethanone 663933-61-7P 663933-62-8P 663933-63-9P 663933-65-1P 663933-66-2P 663933-68-4P 663933-69-5P 663933-70-8P 663933-71-9P 663933-72-0P 663933-74-2P 663933-76-4P 663933-77-5P 663933-78-6P 663933-79-7P 663933-80-0P 663933-81-1P 663933-89-9P 663933-90-2P 663933-91-3P 663933-92-4P 663933-93-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)


RN 452320-31-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.




RN 663933-45-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 663933-46-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-methyl-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 663933-47-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 663933-48-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(methoxymethyl)-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 663933-49-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[[2-methoxyethoxy)methoxy]methyl]-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—CH₂—OMe

RN 663933-50-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-

(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]-, 7-acetate (CA INDEX NAME)




RN 663933-51-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]-7-(phenoxy-methyl)- (CA INDEX NAME)




RN 663933-52-6 CAPLUS

CN Ethanol, 2-[[[3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methyl)methylamino]- (CA INDEX NAME)




RN 663933-53-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl)methyl]-7-(4-morpholinylmethyl)- (CA INDEX NAME)






RN 663933-54-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-, oxime (CA INDEX NAME)




RN 663933-55-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-, O-methyloxime (CA INDEX NAME)




RN 663933-56-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile, 3a,4-dihydro-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)





RN 663933-60-6 CAPLUS


CN Ethanone, 1-[5-[3a,4-dihydro-8-methoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-thienyl]- (CA INDEX NAME)



RN 663933-61-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 663933-62-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.



RN 663933-63-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-
 [(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
 hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




● 2 HCl

RN 663933-65-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[[(2-
 methoxyethoxy)methoxy]methyl]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-
 1-piperazinyl]methyl]-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 663933-64-0
 CMF C31 H41 N3 O6


Relative stereochemistry.
 Double bond geometry as shown.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 663933-66-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-68-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(phoxymethyl)-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 663933-67-3

CMF C33 H37 N3 O4


Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 663933-69-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 663933-70-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, oxime, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as described by E or Z.



RN 663933-71-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carbonitrile, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 663933-72-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 663933-74-2 CAPLUS


CN Acetamide, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]-, ethanedioate (1:1), rel- (CA INDEX NAME)

CM 1

CRN 663933-73-1

CMF C28 H34 N4 O3


Relative stereochemistry.
Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 663933-76-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxamide, N-ethyl-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethanedioate (1:1), (3R,3aS)-rel- (CA INDEX NAME)

CM 1

CRN 663933-75-3

CMF C29 H36 N4 O4


Relative stereochemistry.
Double bond geometry as shown.



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 663933-77-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 663933-78-6 CAPLUS
 CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methyl]methylamino]-, hydrochloride (1:2), rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● 2 HCl

RN 663933-79-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3S,3aR)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 663933-80-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinylmethyl)-, (3R,3aS)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 663933-81-1 CAPLUS

CN Ethanone, 1-[4-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-thienyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 663933-89-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.



RN 663933-90-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(methoxymethyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● 2 HCl


RN 663933-91-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-carboxaldehyde, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 663933-92-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7-methanamine, N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 663933-93-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-[(4-methyl-1-piperidinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B


Me

IT 663933-85-5P 663933-88-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperazinylalkylchromenoisoxazolines as antidepressants)
RN 663933-85-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 7-bromo-3a,4-dihydro-8-methoxy-, ethyl ester (CA INDEX NAME)



RN 663933-88-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-8-methoxy-3-[[4-
 [(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]- (CA INDEX
 NAME)

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:892834 CAPLUS
 DOCUMENT NUMBER: 139:365764
 TITLE: Diblock copolymers for use in pharmaceutical dosage
 forms
 INVENTOR(S): Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli;
 Nathan, Aruna; Rosenblatt, Joel; Ould-Ouali, Louisa
 Myriam; Preat, Veronique
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093344	A1	20031113	WO 2003-EP4368	20030424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082878	A1	20031009	WO 2003-EP3245	20030327
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2480113	A1	20031009	CA 2003-2480113	20030327
AU 2003219111	A1	20031013	AU 2003-219111	20030327
BR 2003008309	A	20041228	BR 2003-8309	20030327
EP 1492796	A1	20050105	EP 2003-714897	20030327
EP 1492796	B1	20070905		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1642960	A	20050720	CN 2003-807419	20030327
JP 2005522469	T	20050728	JP 2003-580343	20030327
NZ 536109	A	20060630	NZ 2003-536109	20030327
AT 372342	T	20070915	AT 2003-714897	20030327
ES 2292949	T3	20080316	ES 2003-714897	20030327
TW 286138	B	20070901	TW 2003-92107328	20030401
MX 2004PA08626	A	20041206	MX 2004-PA8626	20040906
IN 2004DN02809	A	20050401	IN 2004-DN2809	20040921
ZA 2004007904	A	20051020	ZA 2004-7904	20040930
US 20050222125	A1	20051006	US 2004-510220	20041001
US 7265103	B2	20070904		
NO 2004004645	A	20041027	NO 2004-4645	20041027
PRIORITY APPLN. INFO.:			EP 2002-76239	A 20020402
			WO 2003-EP3245	W 20030327
OTHER SOURCE(S):	MARPAT 139:307799			
IT	612074-52-9P 612074-55-2P 612074-58-5P 612074-59-6P 612074-62-1P 612074-63-2P			
RL:	PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of isoxazoline derivs. as antidepressants)			
RN	612074-52-9 CAPLUS			
CN	3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)			


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-55-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-58-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-59-6 CAPLUS

CN 1,2-Ethanediamine, N2-[(3R,3aR)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N1-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-62-1 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazin-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-63-2 CAPLUS

CN 3H,7H-Isioxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT	612074-51-8P	612074-53-0P	612074-54-1P
	612074-56-3P	612074-57-4P	612074-60-9P
	612074-61-0P	612074-64-3P	612074-65-4P
	612074-66-5P	612074-67-6P	612074-68-7P
	612074-69-8P	612074-70-1P	612074-71-2P
	612074-72-3P	612074-73-4P	612074-74-5P
	612074-75-6P	612074-76-7P	612074-77-8P
	612074-78-9P	612074-79-0P	612074-80-3P
	612074-81-4P	612074-82-5P	612074-83-6P
	612074-84-7P	612074-85-8P	612074-86-9P
	612074-87-0P	612074-88-1P	612074-89-2P
	612074-90-5P	612074-91-6P	612074-92-7P
	612074-93-8P	612074-94-9P	612074-95-0P
	612074-96-1P	612074-97-2P	612074-98-3P
	612074-99-4P	612075-00-0P	612075-01-1P
	612075-02-2P	612075-03-3P	612075-04-4P
	612075-05-5P	612075-06-6P	612075-07-7P
	612075-08-8P	612075-09-9P	612075-10-2P
	612075-11-3P	612075-12-4P	612075-13-5P
	612075-14-6P	612075-15-7P	612075-16-8P
	612075-17-9P	612075-18-0P	612075-19-1P
	612075-20-4P	612075-21-5P	612075-22-6P
	612075-23-7P	612075-24-8P	612075-25-9P
	612075-26-0P	612075-27-1P	612075-28-2P
	612075-29-3P	612075-30-6P	612075-31-7P
	612075-32-8P	612075-33-9P	612075-34-0P
	612075-35-1P	612075-36-2P	612075-37-3P
	612075-38-4P	612075-39-5P	612075-40-8P
	612075-41-9P	612075-42-0P	612075-43-1P
	612075-44-2P	612075-45-3P	612075-46-4P
	612075-47-5P	612075-48-6P	612075-49-7P
	612075-50-0P	612075-51-1P	612075-52-2P
	612075-53-3P	612075-54-4P	612075-55-5P
	612075-56-6P	612075-57-7P	612075-58-8P
	612075-59-9P	612075-60-2P	612075-61-3P
	612075-62-4P	612075-63-5P	612075-64-6P
	612075-65-7P	612075-66-8P	612075-67-9P
	612075-68-0P	612075-69-1P	612075-70-4P
	612075-71-5P	612075-72-6P	612075-73-7P
	612075-74-8P	612075-75-9P	612075-76-0P
	612075-77-1P	612075-78-2P	612075-79-3P
	612075-80-6P	612075-81-7P	612075-82-8P
	612075-83-9P	612075-84-0P	612075-85-1P

612075-86-2P 612075-87-3P 612075-88-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of isoxazoline derivs. as antidepressants)

RN 612074-51-8 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl


RN 612074-53-0 CAPLUS

CN Benzenesulfonamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




PAGE 1-A



PAGE 1-B


RN 612074-54-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-(4-morpholinyl)-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612074-56-3 CAPLUS
 CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-57-4 CAPLUS
 CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3,4-dimethoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-60-9 CAPLUS

CN Acetamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-61-0 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-64-3 CAPLUS

CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3a,4,8,9-tetrahydro-7-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-65-4 CAPLUS

CN Ethanone, 2-methoxy-1-[(3R,3aS)-3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H,7H-isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazin-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612074-66-5 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine-7-carboxamide, N-ethyl-3a,4,8,9-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612074-67-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-methyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-68-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-69-8 CAPLUS


CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-

Relative stereochemistry.
Double bond geometry as shown.



RN	612074-70-1	CAPLUS
CN	1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N2-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)	

Relative stereochemistry.
Double bond geometry as shown.



PAGE 1-A


PAGE 1-B

 NHMe

RN	612074-71-2	CAPLUS
CN	1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-, rel- (CA INDEX NAME)	

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

NHMe

RN 612074-72-3 CAPLUS
CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● 2 HCl

PAGE 1-B


NMe₂

RN 612074-73-4 CAPLUS
CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



● HCl


PAGE 1-B

NMe₂

RN 612074-74-5 CAPLUS
CN 1,2-Ethanediamine, N2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N1-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

NMe₂

RN 612074-75-6 CAPLUS
 CN 1,2-Ethanediamine, N1,N1-diethyl-N2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N2-methyl-, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




● HCl

PAGE 1-B

—NEt₂

RN 612074-76-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-[2-(1-pyrrolidiny]ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.




RN 612074-77-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidiny]ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612074-78-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612074-79-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612074-80-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-[2-(4-morpholinyl)ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 612074-81-4 CAPLUS
CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-

yl)methylamino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-82-5 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-83-6 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-84-7 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-

yl]-1-piperazinyl)methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-85-8 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-86-9 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-87-0 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-


yl]-1-piperazinyl)methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-88-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612074-89-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-N-phenyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-90-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(4-fluorophenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612074-91-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(4-methoxyphenyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

— OMe


RN 612074-92-7 CAPLUS
CN Benzonitrile, 3-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-93-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-(2-methylphenyl)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612074-94-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(3,4-dimethylphenyl)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-95-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612074-96-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-N-(phenylmethyl)-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 612074-97-2 CAPLUS

CN Acetamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-98-3 CAPLUS

CN Propanamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-


2,2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612074-99-4 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-00-0 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-01-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-02-2 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-03-3 CAPLUS
CN Benzamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-04-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 612075-05-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 612075-06-6 CAPLUS
CN Carbamic acid, [(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-07-7 CAPLUS
CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-ethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-08-8 CAPLUS

CN Imidodicarbonic diamide, N,N'-diethyl-2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-09-9 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(1,1-dimethylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-10-2 CAPLUS

CN Urea, N-cyclohexyl-N'-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-11-3 CAPLUS

CN Glycine, N-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]carbonyl]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-12-4 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-13-5 CAPLUS

CN Urea, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-(3-fluorophenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-14-6 CAPLUS

CN Methanesulfonamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N-(methylsulfonyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-15-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-16-8 CAPLUS


CN 1-Piperazinecarboximidamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-4-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612075-17-9 CAPLUS
CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-pyrrolidinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-19-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-piperidinyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-20-4 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A





—OEt

RN 612075-21-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(3,4-dihydro-2(1H)-isoquinolinyl)-3-
[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-
3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-22-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-
methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-methyl-1-
piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-23-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-24-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-25-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-26-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-phenyl-1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-27-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-[4-(phenylmethyl)-1-piperazinyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




PAGE 1-A

— Ph

RN 612075-28-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



E — Ph

RN 612075-29-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-30-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-


morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-31-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-32-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-morpholinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-33-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-34-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



●2 HCl


RN 612075-35-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3a,4-dihydro-8-methoxy-N-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 612075-36-2 CAPLUS
 CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-37-3 CAPLUS
 CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-38-4 CAPLUS

CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
3a,4,8,9-tetrahydro-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-
piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-39-5 CAPLUS

CN 3H,7H-Isloxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine,
3a,4,8,9-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-,
(3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 612075-40-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-amine, 3a,4-dihydro-N-(4-methoxyphenyl)-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-41-9 CAPLUS

CN 3H,7H-Isoxazolo[3',4':4,5]pyrano[2,3-g][1,4]benzoxazine, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4,8,9-tetrahydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 612075-42-0 CAPLUS


CN 2-Propenoic acid, 2-methyl-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 612075-43-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-1-pyrrolidinyl-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-44-2 CAPLUS

CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-45-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(1-ethylpropyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-46-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(1-methylpropyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-47-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-4-pyridinyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-48-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(2-methyl-1-pyrrolidinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 612075-49-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(1-azetidiny)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-50-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-7-(4-methyl-1-piperidiny)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-51-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylbutyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-52-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-ethyl-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-


methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-53-3 CAPLUS
CN 2-Propenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-54-4 CAPLUS
CN 2-Azetidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-55-5 CAPLUS
CN Cyclobutanecarboxylic acid, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-


methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612075-56-6 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl)methylamino]ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-57-7 CAPLUS


CN 1,2-Ethanediamine, N2-(1,2-dimethylpropyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 612075-58-8 CAPLUS

CN 1,2-Ethanediamine, N2-cyclobutyl-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-59-9 CAPLUS

CN 2-Butenamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as described by E or Z.

PAGE 1-A



PAGE 1-B


Me

RN 612075-60-2 CAPLUS

CN Pentanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 612075-61-3 CAPLUS
 CN Butanamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-62-4 CAPLUS
 CN Cyclobutanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-63-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-(2-methylpropyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 612075-64-6 CAPLUS

CN Butanoic acid, 3,3-dimethyl-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-65-7 CAPLUS

CN 1,2-Ethanediamine, N2-(cyclopropylmethyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612075-66-8 CAPLUS
CN 2-Propanol, 1-[[2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612075-67-9 CAPLUS
CN 1,2-Ethanediamine, N2-(1,1-dimethylpropyl)-N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612075-68-0 CAPLUS
CN 1,2-Ethanediamine, N1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-N2-2-propen-1-yl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 612075-69-1 CAPLUS
CN 1,2-Ethanediamine, N1-(1,1-dimethylethyl)-N2-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—Bu-t


RN 612075-70-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-[2-(1-azetidiny)ethyl]-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-methyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 612075-71-5 CAPLUS
CN Urea, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N'-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-72-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(hexahydro-1H-azepin-1-yl)-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 612075-73-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(2-methylcyclopropyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.





PAGE 1-A



RN 612075-74-8 CAPLUS

CN Carbamic acid, (1-methylpropyl)-, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propenyl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]methylamino]ethyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-75-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-N-[(1-methylcyclopropyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-76-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(1-methylethyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-77-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, N-(cyclopropylmethyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-78-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-(1-methylpropyl)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-79-3 CAPLUS


CN 2-Propanol, 1-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-80-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-amine, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-N-pentyl-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-81-7 CAPLUS
CN 1-Propanol, 2-[[[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-82-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(3,6-dihydro-1(2H)-pyridinyl)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-83-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7-(1-piperazinyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-84-0 CAPLUS
CN Urea, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-85-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-


[1]benzopyrano[4,3-c]isoxazol-7-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-86-2 CAPLUS
CN 2-Pyrrolidinone, 1-[(3R,3aS)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-3-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 612075-87-3 CAPLUS
CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[[[(1R,2S)-2-phenylcyclopropyl]methyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 612075-88-4 CAPLUS
CN 1,2-Ethanediamine, N1-[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-N1,N2,N2-trimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 452319-29-8P 612075-92-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of isoxazoline derivs. as antidepressants)
RN 452319-29-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-
methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 612075-92-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 7-fluoro-3a,4-dihydro-
, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 452319-78-7 612075-96-4 612075-97-5
612075-98-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoxazoline derivs. as antidepressants)

RN 452319-78-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-96-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-97-5 CAPLUS

CN Carbamic acid, [(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 612075-98-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-bromo-3a,4-dihydro-8-methoxy-3-[[4-
[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-,
(3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:535065 CAPLUS

DOCUMENT NUMBER: 139:292184

TITLE: Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-
c]isoxazoles, displaying combined 5-HT uptake
inhibiting and α 2-adrenoceptor antagonistic
activities: a novel series of potential
antidepressants

AUTHOR(S): Andres, J. Ignacio; Alcazar, Jesus; Alonso, Jose M.;
Alvarez, Rosa M.; Cid, Jose M.; De Lucas, Ana I.;
Fernandez, Javier; Martinez, Sonia; Nieto, Carmen;
Pastor, Joaquin; Bakker, Margot H.; Biesmans, Ilse;
Heylen, Lieve I.; Megens, Anton A.

CORPORATE SOURCE: Division of Janssen-Cilag, Medicinal Chemistry
Department, Jarama s/n, Johnson & Johnson
Pharmaceutical Research & Development, Toledo, 45007,
Spain

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003),
13(16), 2719-2725
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:292184

IT 452313-36-9P 452313-43-8P 452313-54-1P
452313-56-3P 452313-77-8P 452314-18-0P
452316-09-5P 452316-15-3P 452316-21-1P
452316-33-5P 452316-36-8P 452316-66-4P
452316-84-6P 452318-20-6P 452318-24-0P
452318-26-2P 452318-93-3P 452318-95-5P
452318-97-7P 452319-25-4P 452319-35-6P
452320-01-3P 608146-10-7P 608146-11-8P
608146-12-9P 608146-13-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)

(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as
5-HT uptake inhibitors and α 2-adrenoceptor antagonists (potential
antidepressants))

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-43-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 452313-56-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-


3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 452313-77-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-18-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-09-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-15-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-21-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-33-5 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-36-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-66-4 CAPLUS
 CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-84-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-24-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-26-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 452318-97-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 452319-25-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-35-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-01-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 608146-10-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-11-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-12-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 608146-13-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 452321-82-3P 452321-89-0P 608146-03-8P

608146-04-9P 608146-05-0P 608146-06-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydro[1]benzopyrano[4,3-c]isoxazoles and their activity as 5-HT uptake inhibitors and α_2 -adrenoceptor antagonists (potential antidepressants))

RN 452321-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-89-0 CAPLUS

CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]ethyl]triphenyl-, bromide (1:1), rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-03-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-04-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-05-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-7-methoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 608146-06-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-8-methoxy-, ethyl ester, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:658130 CAPLUS

DOCUMENT NUMBER: 137:201298

TITLE: Preparation of substituted isoxazolines as anti-depressants

INVENTOR(S): Andres-Gil, Jose Ignacio; Fernandez-Gadea, Francisco Javier; Alcazar-Vaca, Manuel Jesus; Cid-Nunez, Jose Maria; Pastor-Fernandez, Joaquin; Megens, Antonius Adrianus Hendrikus Petrus; Heylen, Godelieve Irma Christine Maria; Langlois, Xavier Jean Michel; Bakker, Margaretha Henrica Maria; Steckler, Thomas Horst Wolfgang

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----


WO 2002066484	A1	20020829	WO 2002-EP1567	20020213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437505	A1	20020829	CA 2002-2437505	20020213
AU 2002244717	A1	20020904	AU 2002-244717	20020213
AU 2002244717	B2	20070719		
EP 1368358	A1	20031210	EP 2002-712909	20020213
EP 1368358	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300398	A	20031215	EE 2003-398	20020213
HU 2003003270	A2	20040128	HU 2003-3270	20020213
HU 2003003270	A3	20070328		
CN 1492871	A	20040428	CN 2002-805243	20020213
NZ 526741	A	20040430	NZ 2002-526741	20020213
BR 2002007433	A	20040601	BR 2002-7433	20020213
JP 2004518748	T	20040624	JP 2002-565998	20020213
JP 3953424	B2	20070808		
AT 337322	T	20060915	AT 2002-712909	20020213
ES 2271230	T3	20070416	ES 2002-712909	20020213
EG 23929	A	20080114	EG 2002-197	20020219
TW 257392	B	20060701	TW 2002-91102853	20020220
IN 2003DN00968	A	20070525	IN 2003-DN968	20030624
BG 107984	A	20040930	BG 2003-107984	20030708
MX 2003PA07432	A	20031118	MX 2003-PA7432	20030819
NO 2003003700	A	20031021	NO 2003-3700	20030820
ZA 2003006487	A	20041122	ZA 2003-6487	20030820
US 20040122037	A1	20040624	US 2003-468555	20030821
US 7169786	B2	20070130		
PRIORITY APPLN. INFO.:			EP 2001-200611	A 20010221
			EP 2001-201264	A 20010405
			WO 2002-EP1567	W 20020213
OTHER SOURCE(S): MARPAT 137:201298				
IT	452321-67-4P 452321-82-3P 452321-85-6P			
	452321-87-8P 452321-89-0P 452321-91-4P			
	452321-93-6P 452321-95-8P 452321-97-0P			
	452321-99-2P 452322-05-3P 452322-19-9P			
	452322-21-3P 452322-29-1P 452322-30-4P			
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(intermediate; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)				
RN	452321-67-4 CAPLUS			
CN	3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-7,8-dimethoxy-, methyl ester, (3R,3aS)-rel- (CA INDEX NAME)			

Relative stereochemistry.




Chemical structure of compound 10: A 3,4-dimethoxyphenyl ring is fused to a 2,3-dihydro-1,4-benzodioxine system. The dioxine ring has a tert-butoxycarbonyl (t-BuO-C(=O)-) group attached to the nitrogen at position 2. The stereochemistry at the bridgehead carbons is indicated: the sulfur atom is on a wedge and the hydrogen atom is on a dash.

Relative stereochemistry.




Relative stereochemistry.



RN 452321-89-0 CAPLUS
 CN Phosphonium, [2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethyl]triphenyl-, bromide (1:1), rel- (CA INDEX NAME)


Relative stereochemistry.



● Br⁻


RN 452321-91-4 CAPLUS
 CN 2-Propen-1-one, 1-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-3-iodo-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.




RN 452321-93-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-iodo-2-methyl-2-propen-1-yl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452321-95-8 CAPLUS
CN 1-Piperazineethanol, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-α-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-97-0 CAPLUS
CN 1,2-Propanediol, 3-[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperaziny]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-99-2 CAPLUS
CN 1-Piperazineacetaldehyde, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-05-3 CAPLUS

CN Isioxazolo[4,3-c]quinoline-3-carboxylic acid, 3,3a,4,5-tetrahydro-5-(2,2,2-trifluoroacetyl)-, methyl ester, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-19-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxy-5-(2,2,2-trifluoroacetyl)isoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-21-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[(3R,3aR)-3,3a,4,5-tetrahydro-7,8-dimethoxyisoxazolo[4,3-c]quinolin-3-yl]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-29-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]amino]methyl]-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452322-30-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-(4-piperidinylmethyl)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452323-46-5D, resin bound


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452323-46-5 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(diphenylphosphino)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 452313-32-5P 452313-68-7P 452313-71-2P
452313-80-3P 452313-82-5P 452316-78-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted
isoxazolines as anti-depressants)
RN 452313-32-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-
3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2),
(3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



● 2 HCl

RN 452313-68-7 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-
methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel-(+)-
(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-71-2 CAPLUS

CN Isioxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aS)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-80-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




● 2 HCl

RN 452313-82-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2),

(3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.




● 2 HCl

RN 452316-78-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



● 2 HCl


IT 452313-59-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation and pharmaceutical activity of substituted isoxazolines as anti-depressants)

RN 452313-59-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT	452313-36-9P	452313-40-5P	452313-43-8P
	452313-46-1P	452313-50-7P	452313-54-1P
	452313-56-3P	452313-61-0P	452313-65-4P
	452313-74-5P	452313-77-8P	452313-85-8P
	452313-88-1P	452313-91-6P	452313-93-8P
	452313-98-3P	452314-01-1P	452314-05-5P
	452314-08-8P	452314-11-3P	452314-14-6P
	452314-18-0P	452314-20-4P	452314-23-7P
	452314-26-0P	452314-29-3P	452314-31-7P
	452314-34-0P	452314-37-3P	452314-40-8P
	452314-43-1P	452314-46-4P	452314-49-7P
	452314-52-2P	452314-55-5P	452314-57-7P
	452314-60-2P	452314-62-4P	452314-65-7P
	452314-68-0P	452314-71-5P	452314-74-8P
	452314-77-1P	452314-80-6P	452314-83-9P
	452314-86-2P	452314-89-5P	452314-92-0P
	452314-95-3P	452314-98-6P	452315-01-4P
	452315-04-7P	452315-07-0P	452315-10-5P
	452315-13-8P	452315-16-1P	452315-19-4P
	452315-22-9P	452315-24-1P	452315-27-4P
	452315-30-9P	452315-33-2P	452315-36-5P
	452315-38-7P	452315-40-1P	452315-42-3P
	452315-44-5P	452315-46-7P	452315-48-9P
	452315-51-4P	452315-52-5P	452315-55-8P
	452315-58-1P	452315-61-6P	452315-63-8P
	452315-66-1P	452315-70-7P	452315-73-0P
	452315-76-3P	452315-79-6P	452315-82-1P
	452315-85-4P	452315-87-6P	452315-90-1P
	452315-92-3P	452315-94-5P	452315-97-8P
	452316-00-6P	452316-03-9P	452316-06-2P
	452316-09-5P	452316-12-0P	452316-15-3P
	452316-18-6P	452316-21-1P	452316-24-4P
	452316-27-7P	452316-30-2P	452316-33-5P
	452316-36-8P	452316-39-1P	452316-42-6P
	452316-45-9P	452316-48-2P	452316-51-7P
	452316-53-9P	452316-55-1P	452316-58-4P
	452316-64-2P	452316-66-4P	452316-69-7P
	452316-72-2P	452316-75-5P	452316-81-3P
	452316-84-6P	452316-87-9P	452316-89-1P
	452316-91-5P	452316-93-7P	452316-95-9P
	452316-97-1P	452316-99-3P	452317-02-1P
	452317-04-3P	452317-06-5P	452317-08-7P
	452317-10-1P	452317-12-3P	452317-14-5P
	452317-16-7P	452317-18-9P	452317-20-3P
	452317-22-5P	452317-24-7P	452317-26-9P
	452317-28-1P	452317-30-5P	452317-32-7P
	452317-34-9P	452317-36-1P	452317-38-3P
	452317-40-7P	452317-42-9P	452317-44-1P
	452317-46-3P	452317-48-5P	452317-50-9P
	452317-52-1P	452317-54-3P	452317-56-5P

452317-58-7P 452317-60-1P 452317-64-5P
 452317-67-8P 452317-69-0P 452317-71-4P
 452317-73-6P 452317-76-9P 452317-79-2P
 452317-82-7P 452317-84-9P 452317-86-1P
 452317-89-4P 452317-92-9P 452317-94-1P
 452317-96-3P 452317-99-6P 452318-02-4P
 452318-04-6P 452318-07-9P 452318-09-1P
 452318-11-5P 452318-13-7P 452318-15-9P
 452318-18-2P 452318-20-6P 452318-22-8P
 452318-24-0P 452318-27-3P 452318-30-8P
 452318-32-0P 452318-34-2P 452318-36-4P
 452318-38-6P 452318-41-1P 452318-43-3P
 452318-45-5P 452318-47-7P 452318-49-9P
 452318-52-4P 452318-54-6P 452318-57-9P
 452318-60-4P 452318-63-7P 452318-65-9P
 452318-67-1P 452318-69-3P 452318-71-7P
 452318-73-9P 452318-75-1P 452318-77-3P
 452318-79-5P 452318-81-9P 452318-83-1P
 452318-85-3P 452318-87-5P 452318-89-7P
 452318-91-1P 452318-93-3P 452318-95-5P
 452318-97-7P 452318-99-9P 452319-01-6P
 452319-03-8P 452319-05-0P 452319-07-2P
 452319-09-4P 452319-11-8P 452319-13-0P
 452319-15-2P 452319-17-4P 452319-20-9P
 452319-22-1P 452319-24-3P 452319-25-4P
 452319-27-6P 452319-29-8P 452319-31-2P
 452319-33-4P 452319-35-6P 452319-37-8P
 452319-39-0P 452319-41-4P 452319-43-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(target compound; preparation and pharmaceutical activity of substituted
 isoxazolines as anti-depressants)

RN 452313-36-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-
 3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX
 NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452313-40-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-
 2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-
 (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452313-43-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452313-46-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-50-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-54-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-56-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452313-61-0 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452313-65-4 CAPLUS


CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452313-74-5 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452313-77-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452313-85-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452313-88-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452313-91-6 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methylphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452313-93-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dihydro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452313-98-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452314-01-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.



RN 452314-05-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-buten-1-yl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452314-08-8 CAPLUS


CN 1-Piperazineethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-methyl-N-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-11-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-14-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452314-18-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-20-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-23-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[3-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-26-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-29-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[[2-(1,1,2,2-tetrafluoroethyl)phenyl]methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-31-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452314-34-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452314-37-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452314-40-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-43-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl


RN 452314-46-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452314-49-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-nitrophenyl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-52-2 CAPLUS

CN Benzenamine, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 452314-55-5 CAPLUS


CN Acetamide, N-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]phenyl]- (CA INDEX NAME)




RN 452314-57-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2-ethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452314-60-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenoxyphenyl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-62-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(4-phenoxyphenyl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-65-7 CAPLUS
 CN 1-Propanamine, 3-[4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]phenoxy]-N,N-dimethyl- (CA INDEX NAME)




RN 452314-68-0 CAPLUS
 CN Benzoic acid, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]-, methyl ester (CA INDEX NAME)



RN 452314-71-5 CAPLUS
 CN Benzonitrile, 3-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]- (CA INDEX NAME)




RN 452314-74-8 CAPLUS
 CN Benzonitrile, 4-[[4-[(3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452314-77-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-([1,1'-biphenyl]-3-yl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-80-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452314-83-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452314-86-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452314-89-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(3,4-dichlorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-92-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromo-2-fluorophenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-95-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methyl-1H-pyrrol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452314-98-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-01-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thiazolylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-04-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-4-thiazolyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-07-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-10-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-13-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-methyl-2-furanyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-16-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-furanylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-19-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-22-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-24-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-27-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-30-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(4-bromo-2-thienyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-33-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-thienylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-36-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[3,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-38-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[2,5-dimethyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-40-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[3-methyl-4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-42-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452315-44-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(1-naphthalenylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452315-46-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(1-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-48-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-51-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-52-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(7-

methyl-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 452315-55-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(6-methyl-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 452315-58-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(3-methyl-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-, (3R,3aS)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 452315-61-6 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA
INDEX NAME)

Relative stereochemistry.




RN 452315-63-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452315-66-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452315-70-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-chloro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-73-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(1-bromo-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-76-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(5-nitro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-79-6 CAPLUS

CN 1-Naphthalenamine, 6-[[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-82-1 CAPLUS

CN 1-Naphthalenamine, 6-[[4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl)methyl]-N,N-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-85-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-87-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5,7-difluoro-2-naphthalenyl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-90-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7,8-difluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-92-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(5-bromo-8-methoxy-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-94-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452315-97-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-indol-3-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-00-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-03-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-benzofuranylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride (1:2),

(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-06-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-09-5 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(benzo[b]thien-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-12-0 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-quinolinylmethyl)-1-piperazinyl]methyl]- (CA INDEX NAME)



RN 452316-15-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-18-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(4-quinolinylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-21-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-phenylethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-24-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yl)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-27-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-30-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(1-naphthalenyl)ethyl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-33-5 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-36-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(1H-inden-2-ylmethyl)-1-piperazinyl]methyl]-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-39-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-42-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452316-45-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(1,3-benzodioxol-5-yloxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-48-2 CAPLUS

CN 1H-Inden-1-one, 5-[2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]ethoxy]-2,3-dihydro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-51-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-[(2,3-dihydro-5-benzofuranyloxy)ethyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-53-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[2-(3-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-55-1 CAPLUS
CN 3(2H)-Benzofuranone, 6-[2-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methylethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-58-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[[(2R)-6-fluoro-3,4,4a,8a-tetrahydro-2H-1-benzopyran-2-yl]methyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-64-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(1,3-benzodioxol-2-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452316-66-4 CAPLUS
 CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452316-69-7 CAPLUS
 CN 1-Piperazinepropanol, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452316-72-2 CAPLUS

CN 1-Propanone, 3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-phenyl-, oxime, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452316-75-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452316-81-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452316-84-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452316-87-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● 2 HCl

RN 452316-89-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl

RN 452316-91-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


RN 452316-93-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-phenoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452316-95-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452316-97-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452316-99-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-02-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● 2 HCl

RN 452317-04-3 CAPLUS

CN Naphth[1,2-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.


Double bond geometry as shown.



RN 452317-06-5 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-08-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-10-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-chlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-12-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-14-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-16-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-bromophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-18-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.




RN 452317-20-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[3-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.



RN 452317-22-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.



RN 452317-24-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-[2-(1,1,2,2-tetrafluoroethyl)phenyl]-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-26-9 CAPLUS

CN Benzoic acid, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-28-1 CAPLUS


CN Benzoic acid, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-30-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-nitrophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-32-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-nitrophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-34-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-methylphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-36-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-phenoxyphenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-38-3 CAPLUS
CN Benzonitrile, 2-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-40-7 CAPLUS
CN Benzonitrile, 3-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)

rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-42-9 CAPLUS

CN Benzonitrile, 4-[3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-1-piperazinyl]-1-propen-1-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-44-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-2-yl-2-propen-1-yl)-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-46-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,4-difluorophenyl)-2-propen-

1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452317-48-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,4-difluorophenyl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452317-50-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,3-difluorophenyl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452317-52-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,6-difluorophenyl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-54-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,5-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-56-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(3,5-difluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-58-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,6-dichlorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-


(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-60-1 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chloro-4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)



RN 452317-64-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-chloro-6-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452317-67-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-dihydro-1H-inden-5-


yl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452317-69-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452317-71-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(9H-fluoren-2-yl)-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-73-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-dibenzofuranyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452317-76-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(1,3-benzodioxol-5-yl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452317-79-2 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-dihydro-5-benzofuranyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452317-82-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4,5-dimethoxy-2-nitrophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.




RN 452317-84-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.




RN 452317-86-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.




RN 452317-89-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)-
 (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
 Double bond geometry as shown.



RN 452317-92-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-bromo-2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.



RN 452317-94-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(5-bromo-2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-96-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(2-furanyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452317-99-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(3-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 452318-02-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-04-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[5-(4-chlorophenyl)-2-furanyl]-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-07-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-naphthalenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 452318-09-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(1-naphthalenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


RN 452318-11-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(4-quinolinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-13-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[3-(2-quinolinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-15-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(9-anthracenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 452318-18-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-1-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452318-20-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-22-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 452318-24-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-

2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3S,3aR)-rel-(-)-
(CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-27-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl)methyl]-, (3R,3aS)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 452318-26-2

CMF C27 H33 N3 O4

Relative stereochemistry.
Double bond geometry as shown.




CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



RN 452318-30-8 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[[(2R,5S)-2,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-32-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(3S,5R)-3,5-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-34-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[(2S,6R)-2,6-dimethyl-4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.




RN 452318-36-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2Z)-

2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aS)-rel-
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-38-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(2-methyl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 452318-41-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2,3-diphenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy- (CA INDEX NAME)




RN 452318-43-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2-[1,1'-biphenyl]-4-yl-3-phenyl-2-propen-1-yl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-45-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyl)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-47-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-(phenylmethylene)butyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 452318-49-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-(phenylmethylene)heptyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452318-52-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-bromo-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452318-54-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-chloro-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452318-57-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-2-fluoro-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-60-4 CAPLUS

CN 1-Piperazinepropanenitrile, 4-[[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-α-(phenylmethylene)-, (αZ)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-63-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-65-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(3-[1,1'-biphenyl]-4-yl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 452318-67-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452318-69-3 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-71-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-73-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-75-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 452318-77-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-79-5 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-chloro-6-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-81-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452318-83-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452318-85-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-87-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,3-difluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-89-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[2-methyl-3-(1-naphthalenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 452318-91-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-(2H-1-benzopyran-3-ylmethyl)-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452318-93-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452318-95-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452318-97-7 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 452318-99-9 CAPLUS
 CN Phenol, 3-[(1E)-3-[4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-methyl-1-propen-1-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-01-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-thienyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-03-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-thienyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-05-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,5-dimethyl-3-thienyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-07-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-09-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(3-pyridinyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-11-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-2-methyl-3-(2-methyl-4-thiazolyl)-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-13-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2-phenyl-1-cyclopenten-1-yl)methyl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452319-15-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-(3-phenyl-2-propyn-1-yl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452319-17-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452319-20-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[3-(4-fluorophenoxy)propyl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452319-22-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-4-(2-fluorophenyl)-2-methyl-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 452319-24-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E,4E)-5-phenyl-2,4-pentadien-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452319-25-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-27-6 CAPLUS
 CN Benzoic acid, 4-[(1E)-3-[4-[(3R,3aS)-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl]methyl]-1-piperazinyl]-1-propen-1-yl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-29-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-31-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-33-4 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-35-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-37-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
 Double bond geometry as shown.



● 2 HCl

RN 452319-39-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3S,3aR)-rel-(-)- (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.
 Double bond geometry as shown.



● 2 HCl


RN 452319-41-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-43-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-(2-methoxyethoxy)-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



IT 452319-45-8P 452319-47-0P 452319-49-2P
 452319-51-6P 452319-53-8P 452319-55-0P
 452319-57-2P 452319-59-4P 452319-61-8P
 452319-63-0P 452319-65-2P 452319-67-4P
 452319-69-6P 452319-71-0P 452319-73-2P
 452319-75-4P 452319-77-6P 452319-78-7P
 452319-80-1P 452319-81-2P 452319-83-4P
 452319-85-6P 452319-87-8P 452319-89-0P
 452319-91-4P 452319-93-6P 452319-95-8P

452319-97-0P 452319-99-2P 452320-01-3P
 452320-03-5P 452320-06-8P 452320-07-9P
 452320-09-1P 452320-11-5P 452320-13-7P
 452320-15-9P 452320-17-1P 452320-19-3P
 452320-21-7P 452320-23-9P 452320-25-1P
 452320-27-3P 452320-29-5P 452320-31-9P
 452320-34-2P 452320-36-4P 452320-38-6P
 452320-40-0P 452320-42-2P 452320-44-4P
 452320-46-6P 452320-48-8P 452320-50-2P
 452320-52-4P 452320-54-6P 452320-56-8P
 452320-58-0P 452320-60-4P 452320-62-6P
 452320-64-8P 452320-66-0P 452320-68-2P
 452320-70-6P 452320-72-8P 452320-74-0P
 452320-76-2P 452320-78-4P 452320-80-8P
 452320-82-0P 452320-84-2P 452320-86-4P
 452320-88-6P 452320-90-0P 452320-92-2P
 452320-94-4P 452320-96-6P 452320-98-8P
 452321-00-5P 452321-02-7P 452321-04-9P
 452321-06-1P 452321-08-3P 452321-10-7P
 452321-12-9P 452321-14-1P 452321-16-3P
 452321-19-6P 452321-21-0P 452321-23-2P
 452321-25-4P 452321-27-6P 452321-29-8P
 452321-31-2P 452321-33-4P 452321-35-6P
 452321-37-8P 452321-39-0P 452321-41-4P
 452321-43-6P 452321-45-8P 452321-47-0P
 452321-49-2P 452321-51-6P 452321-53-8P
 452321-55-0P 452321-57-2P 452321-59-4P
 452321-61-8P 452934-93-9P 452934-94-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(target compound; preparation and pharmaceutical activity of substituted
 isoxazolines as anti-depressants)

RN 452319-45-8 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-
 methoxyethoxy)methoxy]-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-47-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-
 methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-
 piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.



RN 452319-49-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● 2 HCl


RN 452319-51-6 CAPLUS
 CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-53-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452319-55-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-57-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-propanoate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-59-4 CAPLUS

CN Acetic acid, 2-methoxy-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-61-8 CAPLUS

CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-63-0 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-65-2 CAPLUS

CN 2-Propenoic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-67-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopentyloxy)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-69-6 CAPLUS

CN 4-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-71-0 CAPLUS

CN Ethanamine, 2-[[[(3R,3aS)-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-73-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-(hydrogen sulfate), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-75-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-chloro-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-77-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-chloro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-78-7 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452319-80-1 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 452319-81-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-bromo-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3S,3aR)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

Double bond geometry as shown.




RN 452319-83-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7,8-difluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452319-85-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-fluoro-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452319-87-8 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-phenyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-89-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-91-4 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 8-fluoro-3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(methylthio)-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452319-93-6 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole-7,8-diol, 3a,4-dihydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



● 2 HCl


RN 452319-95-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-97-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-8-ol, 3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 8-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452319-99-2 CAPLUS
 CN Ethanol, 2-[[(3R,3aS)-3a,4-dihydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-8-yl]oxy]-, 1-acetate, rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452320-01-3 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452320-03-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452320-06-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.



RN 452320-07-9 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 452320-09-1 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethoxy)-3-[[4-[(2E)-3-(4-fluorophenyl)-2-methyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-8-methoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-11-5 CAPLUS

CN Cyclopropanecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-13-7 CAPLUS

CN 3-Pyridinecarboxylic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452320-15-9 CAPLUS


CN Carbamic acid, ethyl-, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propenyl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-17-1 CAPLUS
CN Ethanamine, 2-[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-N,N-dimethyl-, rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-19-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-7-[(2-methoxyethoxy)methoxy]-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-21-7 CAPLUS
CN Carbonic acid, (3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-

c]isoxazol-7-yl methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-23-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-7-(2-propen-1-yloxy)-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-25-1 CAPLUS

CN Ethanol, 2-[[[(3R,3aS)-3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3H-[1]benzopyrano[4,3-c]isoxazol-7-yl]oxy]-, hydrochloride (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 452320-27-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, 7-methanesulfonate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-29-5 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-31-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-

methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-7-phenyl-,
(3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-34-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-7-(methylthio)-, (3R,3aS)-rel-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 452320-33-1
CMF C27 H33 N3 O3 S

Relative stereochemistry.
Double bond geometry as shown.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 452320-36-4 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl)methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-38-6 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-40-0 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452320-42-2 CAPLUS
CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-44-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel-(+)-(CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.
Double bond geometry as shown.



RN 452320-46-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3S,3aS)-rel-(-)-(CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.
Double bond geometry as shown.




RN 452320-48-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-propen-1-yl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-50-2 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-52-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 452320-54-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-5-methyl-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 452320-56-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-2-methyl-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-5-(phenylmethyl)-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-58-0 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-60-4 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-2,2,2-trifluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-62-6 CAPLUS

CN Ethanone, 1-[(3R,3aR)-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]isoxazolo[4,3-c]quinolin-5(3H)-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-64-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxylic acid, 3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, ethyl ester, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-66-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline-5(3H)-carboxamide, N-ethyl-3a,4-dihydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-68-2 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-7-methoxy-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 452320-70-6 CAPLUS

CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-72-8 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(phenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-74-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(3-phenylpropyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-76-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 452320-78-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-[(2-methoxyethoxy)methoxy]-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

— OMe


RN 452320-80-8 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-82-0 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(cyclopropylmethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-84-2 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 7-(difluoromethoxy)-3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-86-4 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-7-[(tetrahydro-3-furanyl)oxy]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452320-88-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452320-90-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452320-92-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazol-7-ol, 3a,4-dihydro-8-methoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, 7-acetate, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452320-94-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452320-96-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry as shown.




RN 452320-98-8 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-fluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452321-00-5 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methoxyphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452321-02-7 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[3-(trifluoromethyl)phenyl]-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-
 (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-04-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-06-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-08-3 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-10-7 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(4-chlorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel-
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 452321-12-9 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(4-methylphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-14-1 CAPLUS
CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-methoxyphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-

(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-16-3 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-methoxyphenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel-
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-19-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2Z)-3-fluoro-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, hydrochloride
(1:2), (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




● 2 HCl

RN 452321-21-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-23-2 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(3,4-difluorophenyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-25-4 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-pyridinyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-27-6 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(3-pyridinyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-29-8 CAPLUS


CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7,8-dimethoxy-3-[[4-[(2E)-3-(2-thienyl)-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 452321-31-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(2E)-3-(2-furanyl)-2-buten-1-yl]-1-piperazinyl]methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452321-33-4 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(4-chlorophenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-35-6 CAPLUS
 CN Isoxazolo[4,3-c]quinoline, 3-[[4-[2-(4-fluorophenoxy)ethyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-37-8 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[(2E)-3-phenyl-2-buten-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452321-39-0 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-41-4 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-(6-quinolinylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-43-6 CAPLUS

CN Isoxazolo[4,3-c]quinoline, 3-[[4-[(5-fluoro-2-naphthalenyl)methyl]-1-piperazinyl]methyl]-3,3a,4,5-tetrahydro-7,8-dimethoxy-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-45-8 CAPLUS

CN Isioxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-7,8-dimethoxy-3-[[4-[2-(2-naphthalenyloxy)ethyl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-47-0 CAPLUS

CN Isioxazolo[4,3-c]quinoline, 3,3a,4,5-tetrahydro-5-methyl-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452321-49-2 CAPLUS

CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-(2-naphthalenylmethyl)-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 452321-51-6 CAPLUS
 CN [1,3]Dioxolo[6,7]naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, hydrochloride (1:2), (3R,3aR)-rel- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● 2 HCl


RN 452321-53-8 CAPLUS
 CN Furo[2',3':6,7]naphth[1,2-c]isoxazole, 3,3a,4,5,8,9-hexahydro-3-[[4-[(2E)-3-phenyl-2-propen-1-yl]-1-piperazinyl]methyl]-, (3R,3aR)-rel- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




RN 452321-55-0 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3a,4-dihydro-7-methoxy-3-[2-[4-(2-naphthalenylmethyl)-1-piperazinyl]ethyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-57-2 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-methanamine, 3a,4-dihydro-7,8-dimethoxy-N-methyl-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 452321-59-4 CAPLUS
 CN Formamide, N-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-N-[1-(2-naphthalenylmethyl)-4-piperidinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 452321-61-8 CAPLUS
 CN 1-Piperazinemethanamine, 4-[[(3R,3aS)-3a,4-dihydro-7,8-dimethoxy-3H-[1]benzopyrano[4,3-c]isoxazol-3-yl)methyl]-N-2-naphthalenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452934-93-9 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(7-fluoro-2,3,4a,8a-tetrahydro-1,4-dioxino[2,3-b]pyridin-3-yl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 452934-94-0 CAPLUS

CN 3H-[1]Benzopyrano[4,3-c]isoxazole, 3-[[4-[(6-fluoro-3,4,4a,8a-tetrahydro-4-methyl-2H-1,4-benzoxazin-2-yl)methyl]-1-piperazinyl)methyl]-3a,4-dihydro-7,8-dimethoxy-, (3R,3aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:260283 CAPLUS

DOCUMENT NUMBER: 132:293757
 TITLE: Preparation of novel 4,5-dihydroisoxazole derivatives and their use as pharmaceuticals for T cell-mediated diseases
 INVENTOR(S): Freyne, Eddy Jean Edgard; Andres-Gil, Jose Ignacio; Deroose, Frederik Dirk; Petit, Davy Petrus Franciscus Maria; Matesanz-Ballesteros, Maria Encarnacion; Alvarez Escobar, Rosa Maria
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021959	A1	20000420	WO 1999-EP7803	19991007
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346396	A1	20000420	CA 1999-2346396	19991007
EP 1119568	A1	20010801	EP 1999-953847	19991007
EP 1119568	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527438	T	20020827	JP 2000-575865	19991007
AU 763460	B2	20030724	AU 2000-10393	19991007
AT 259803	T	20040315	AT 1999-953847	19991007
ES 2216579	T3	20041016	ES 1999-953847	19991007
US 6583141	B1	20030624	US 2001-807149	20010406
HK 1038565	A1	20040618	HK 2002-100274	20020115
US 20040019059	A1	20040129	US 2003-403543	20030331
PRIORITY APPLN. INFO.:			EP 1998-203394	A 19981009
			WO 1999-EP7803	W 19991007
			US 2001-807149	A3 20010406

OTHER SOURCE(S): MARPAT 132:293757


IT 264606-16-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of dihydroisoxazole derivs. as antiproliferatives and immunomodulators)

RN 264606-16-8 CAPLUS

CN Piperidine, 4-(4-fluorobenzoyl)-1-[[(3R,3aR)-3,3a,4,5-tetrahydroisoxazolo[4,3-c]quinolin-3-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:431584 CAPLUS
 DOCUMENT NUMBER: 127:149098
 ORIGINAL REFERENCE NO.: 127:28805a,28808a
 TITLE: A convenient synthesis of 3- and 3,4-substituted 4,5-dihydroisoxazole-5-acetic acids
 AUTHOR(S): Eichinger, Karl; Wokurek, Michael; Zauner, Bernd; Rostami, Mohammad Reza
 CORPORATE SOURCE: Institute of Organic Chemistry, Vienna University of Technology, Vienna, A-1060, Austria
 SOURCE: Synthetic Communications (1997), 27(16), 2733-2742
 CODEN: SYNCAV; ISSN: 0039-7911
 PUBLISHER: Dekker
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 127:149098
 IT 193267-45-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of isoxazoleacetic acids)
 RN 193267-45-7 CAPLUS
 CN Naphth[1,2-c]isoxazole-3-acetic acid, 3,3a,4,5-tetrahydro-, (3R,3aS)-rel-
 (CA INDEX NAME)


Relative stereochemistry.




REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:228191 CAPLUS
 DOCUMENT NUMBER: 122:81272
 ORIGINAL REFERENCE NO.: 122:15443a,15446a
 TITLE: Nitrile oxide [3 + 2] cycloaddition: application to the synthesis of 6-substituted 3(2H)-pyridazinones and 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-

pyridazinones
 AUTHOR(S): Baraldi, P. G.; Bigoni, A.; Cacciari, B.; Caldari, C.;
 Manfredini, S.; Spalluto, G.
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Univ. di
 Ferrara, Ferrara, I-44100, Italy
 SOURCE: Synthesis (1994), (11), 1158-62
 CODEN: SYNTBF; ISSN: 0039-7881
 PUBLISHER: Thieme
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 122:81272
 IT 160427-31-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (nitrile oxide [3 + 2] cycloaddn. to pyridazinones)
 RN 160427-31-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-, methyl
 ester (CA INDEX NAME)




L3 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:94454 CAPLUS
 DOCUMENT NUMBER: 123:111970
 ORIGINAL REFERENCE NO.: 123:20005a,20008a
 TITLE: Pyridazin-3(2H)-ones via Δ^2 -isoxazoline
 intermediates: synthetic studies
 AUTHOR(S): Baraldi, Pier Giovanni; Spalluto, Giampiero;
 Manfredini, Stefano; Simoni, Daniele
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università di
 Ferrara, Ferrara, Italy
 SOURCE: Acta Chimica Slovenica (1994), 41(2), 149-72
 CODEN: ACSLE7; ISSN: 1318-0207
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 160427-31-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of benzpyranopyridazinone)
 RN 160427-31-6 CAPLUS
 CN 3H-[1]Benzopyrano[4,3-c]isoxazole-3-carboxylic acid, 3a,4-dihydro-, methyl
 ester (CA INDEX NAME)




L3 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:428382 CAPLUS
 DOCUMENT NUMBER: 119:28382
 ORIGINAL REFERENCE NO.: 119:5269a,5272a
 TITLE: New synthetic strategy for the construction of the BCD ring system of tanshinones
 AUTHOR(S): Shishido, Kozo; Takata, Takeshi; Omodani, Tomoki; Shibuya, Masayuji
 CORPORATE SOURCE: Inst. Med. Resour., Univ. Tokushima, Tokushima, 770, Japan
 SOURCE: Chemistry Letters (1993), (3), 557-60
 CODEN: CMLTAG; ISSN: 0366-7022
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 119:28382
 IT 148117-54-8P 148153-87-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deacetylation of)
 RN 148117-54-8 CAPLUS
 CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro-4,5-bis(methoxymethoxy)-3-methyl-, acetate (ester), (3 α ,3a α ,4 α ,5 β)- (9CI) (CA INDEX NAME)




RN 148153-87-1 CAPLUS
 CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro-4,5-bis(methoxymethoxy)-3-methyl-, acetate (ester), (3 α ,3a α ,4 β ,5 α)- (9CI) (CA INDEX NAME)




L3 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:234262 CAPLUS
 DOCUMENT NUMBER: 118:234262
 ORIGINAL REFERENCE NO.: 118:40591a,40594a
 TITLE: A general synthetic route to fused furans. Total synthesis of (+)-pallascensin A
 AUTHOR(S): Shishido, Kozo; Umimoto, Koji; Ouchi, Mikiko; Irie, Osamu; Omodani, Tomoki; Takata, Takeshi; Shibuya, Masayuki
 CORPORATE SOURCE: Inst. Med. Resour., Univ. Tokushima, Tokushima, 770, Japan

SOURCE: Journal of Chemical Research, Synopses (1993), (2),
58-9
CODEN: JRPSDC; ISSN: 0308-2342
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 147378-11-8P 147378-13-0P 147378-14-1P
147511-14-6P 147511-15-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and deacetylation of)
RN 147378-11-8 CAPLUS
CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro-3-methyl-, acetate
(ester), cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 147378-13-0 CAPLUS
CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α -methyl-,
acetate (ester), [3 α (S*),3 α]- (9CI) (CA INDEX NAME)



RN 147378-14-1 CAPLUS
CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α ,3-dimethyl-,
acetate (ester), [3 α (S*),3 α]- (9CI) (CA INDEX NAME)




RN 147511-14-6 CAPLUS
CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α -methyl-,
acetate (ester), [3 α (R*),3 α]- (9CI) (CA INDEX NAME)



RN 147511-15-7 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α ,3-dimethyl-, acetate (ester), [3 α (R*),3 $\alpha\alpha$]- (9CI) (CA INDEX NAME)




IT 147378-22-1P 147378-23-2P 147511-12-4P
147511-13-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation, hydrolysis, and cyclization of)

RN 147378-22-1 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α -methyl-, [3 α (S*),3 $\alpha\alpha$]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 147378-23-2 CAPLUS

CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α ,3-dimethyl-, [3 α (S*),3 $\alpha\alpha$]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 147511-12-4 CAPLUS


CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α -methyl-, [3 α (R*),3 $\alpha\alpha$]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 147511-13-5 CAPLUS
 CN Naphth[1,2-c]isoxazole-3-methanol, 3,3a,4,5-tetrahydro- α ,3-dimethyl-, [3 α (R*),3 $\alpha\alpha$]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981:462048 CAPLUS
 DOCUMENT NUMBER: 95:62048
 ORIGINAL REFERENCE NO.: 95:10479a,10482a
 TITLE: Fused heterocycles: Part III. Attempted synthesis of 4,5-dihydro-3-arylnaphth[1,2-c]isoxazoles
 AUTHOR(S): Rao, C. Janakiram; Reddy, K. Malla; Murthy, A. Krishna
 CORPORATE SOURCE: Dep. Chem., Kakatiya Univ., Warangal, 506 009, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1981), 20B(4), 282-4
 CODEN: IJSBDB; ISSN: 0376-4699
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 95:62048
 IT 78364-57-5P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 78364-57-5 CAPLUS
 CN Naphth[1,2-c]isoxazole, 3,3a,4,5-tetrahydro-3-(4-methylphenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=>